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A B S T R A C T
Background
This review is an update of a previously published review in the Cochrane Database of Systematic Reviews Issue 1, 2013 on Neuro-
muscular electrical stimulation for muscle weakness in adults with advanced disease.
Patients with advanced progressive disease often experience muscle weakness, which can impact adversely on their ability to be in-
dependent and their quality of life. In those patients who are unable or unwilling to undertake whole-body exercise, neuromuscular
electrical stimulation (NMES) may be an alternative treatment to enhance lower limb muscle strength. Programmes of NMES appear
to be acceptable to patients and have led to improvements in muscle function, exercise capacity, and quality of life. However, estimates
regarding the effectiveness of NMES based on individual studies lack power and precision.
Objectives
Primary objective: to evaluate the effectiveness of NMES on quadriceps muscle strength in adults with advanced disease. Secondary
objectives: to examine the safety and acceptability of NMES, and its effect on peripheral muscle function (strength or endurance),
muscle mass, exercise capacity, breathlessness, and health-related quality of life.
Search methods
We identified studies from searches of the Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Database of
Systematic Reviews (CDSR), and Database of Abstracts of Reviews of Effects (DARE) (the Cochrane Library), MEDLINE (OVID),
Embase (OVID), CINAHL (EBSCO), and PsycINFO (OVID) databases to January 2016; citation searches, conference proceedings,
and previous systematic reviews.
Selection criteria
We included randomised controlled trials in adults with advanced chronic respiratory disease, chronic heart failure, cancer, or HIV/
AIDS comparing a programme of NMES as a sole or adjunct intervention to no treatment, placebo NMES, or an active control. We
imposed no language restriction.
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Data collection and analysis
Two review authors independently extracted data on study design, participants, interventions, and outcomes. We assessed risk of
bias using the Cochrane ’Risk of bias’ tool. We calculated mean differences (MD) or standardised mean differences (SMD) between
intervention and control groups for outcomes with sufficient data; for other outcomes we described findings from individual studies.
We assessed the evidence using GRADE and created a ’Summary of findings’ table.
Main results
Eighteen studies (20 reports) involving a total of 933 participants with COPD, chronic respiratory disease, chronic heart failure, and/
or thoracic cancer met the inclusion criteria for this update, an additional seven studies since the previous version of this review. All
but one study that compared NMES to resistance training compared a programme of NMES to no treatment or placebo NMES. Most
studies were conducted in a single centre and had a risk of bias arising from a lack of participant or assessor blinding and small study
size. The quality of the evidence using GRADE comparing NMES to control was low for quadriceps muscle strength, moderate for
occurrence of adverse events, and very low to low for all other secondary outcomes. We downgraded the quality of evidence ratings
predominantly due to inconsistency among study findings and imprecision regarding estimates of effect. The included studies reported
no serious adverse events and a low incidence of muscle soreness following NMES.
NMES led to a statistically significant improvement in quadriceps muscle strength as compared to the control (12 studies; 781
participants; SMD 0.53, 95% confidence interval (CI) 0.19 to 0.87), equating to a difference of approximately 1.1 kg. An increase in
muscle mass was also observed following NMES, though the observable effect appeared dependent on the assessment modality used
(eight studies, 314 participants). Across tests of exercise performance, mean differences compared to control were statistically significant
for the 6-minute walk test (seven studies; 317 participants; 35 m, 95% CI 14 to 56), but not for the incremental shuttle walk test (three
studies; 434 participants; 9 m, 95% CI -35 to 52), endurance shuttle walk test (four studies; 452 participants; 64 m, 95% CI -18 to
146), or for cardiopulmonary exercise testing with cycle ergometry (six studies; 141 participants; 45 mL/minute, 95% CI -7 to 97).
Limited data were available for other secondary outcomes, and we could not determine the most beneficial type of NMES programme.
Authors’ conclusions
The overall conclusions have not changed from the last publication of this review, although we have included more data, new analyses,
and an assessment of the quality of the evidence using the GRADE approach. NMESmay be an effective treatment for muscle weakness
in adults with advanced progressive disease, and could be considered as an exercise treatment for use within rehabilitation programmes.
Further research is very likely to have an important impact on our confidence in the estimate of effect and may change the estimate. We
recommend further research to understand the role of NMES as a component of, and in relation to, existing rehabilitation approaches.
For example, studies may consider examining NMES as an adjuvant treatment to enhance the strengthening effect of programmes, or
support patients with muscle weakness who have difficulty engaging with existing services.
P L A I N L A N G U A G E S U M M A R Y
Muscle stimulation for weakness in adults with advanced disease
Background
Individual studies suggest that neuromuscular electrical stimulation, or NMES, may help improve the muscle weakness that people
often experience as a consequence of a progressive disease. NMES uses a lightweight stimulator unit and skin electrodes to produce a
controlled and comfortable muscle contraction. Being a passive form of exercise, NMES allows patients to exercise their leg muscles at
home whilst seated. This may be particularly helpful for people who are unable to take part in more strenuous forms of exercise, for
example because of shortness of breath or fatigue.
Key results
In this review update we considered 18 clinical studies comparing NMES to either no exercise, placebo NMES, or weight training
in groups of people with advanced chronic respiratory disease, chronic heart failure, and/or cancer of the lungs. NMES appeared to
be more effective than the control conditions at improving thigh muscle strength. We also observed a positive effect on this outcome
when precise measures were used to assess muscle bulk. The evidence for an effect of NMES on ability to exercise was inconclusive.
Further research is required to understand how NMES can be used within broader rehabilitation approaches that combine exercise
with education and behaviours to reduce the impact of muscle weakness on daily life, for example becoming more physically active.
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Quality of the evidence
We rated the quality of the evidence from studies using four levels: very low, low, moderate, or high. Very low-quality evidence means
that we are very uncertain about the results. High-quality evidence means that we are very confident in the results. Overall, the quality
of the evidence was low for the effect on thigh muscle strength and very low to moderate for the effects on other outcomes. There
were problems with the design of some studies; often people taking part or assessors knew if they were receiving or testing NMES. In
addition, the results for many outcomes were inconsistent or imprecise.
Implications for practice and research
This review suggests that NMES is a potentially effective treatment for muscle weakness in people with progressive diseases such as
cancer, advanced chronic respiratory disease, and chronic heart failure, though the quality of the evidence is low. NMES might be
considered for use within rehabilitation programmes. It was not possible to compare the effects of NMES to other forms of exercise,
for example weight training, because the majority of studies compared NMES to a control group that received no treatment or a sham
treatment. Further research is needed to understand the effect of NMES on the ability to exercise and quality of life.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
NM ES for adults with advanced disease for muscle weakness
Patient or population: adults with advanced disease for muscle weakness
Settings: hospital, community, or home sett ings
Intervention: NMES
Control: no intervent ion (7 studies), placebo NMES (8 studies), or resistance training (1 study)
Outcomes Illustrative comparative risks* (95% CI) No of Participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Control NM ES
Quadriceps muscle
strength
Handheld or f ixed dy-
namometry
Follow-up: median 6
weeks
The mean change was
0.43 standard devia-
t ions f rom baseline.
The mean change in
the intervent ion groups
was 0.53 standard de-
viations higher (rang-
ing f rom 0.19 to 0.
87 standard deviat ions
higher).
781
(12 studies)
⊕⊕©©
low1,2
Safety
Serious adverse events
Follow-up: median 6
weeks
No serious adverse
events related to con-
trol intervent ions re-
ported
No serious adverse
events related to NMES
reported.
933
(18 studies)
⊕⊕⊕©
moderate3
Safety
Adverse events: Muscle
discomfort
Follow-up: median 6
weeks
0/ 415 (0%) part icipants
reported muscle dis-
comfort following con-
trol intervent ions
19/ 518 (3.7%) part ic-
ipants reported mus-
cle discomfort f ollow-
ing NMES.
933
(18 studies)
⊕⊕⊕©
moderate3
M uscle mass
Anthropometry, DEXA,
ultrasound, computed
tomography
Follow-up: 4 to 9 weeks
The mean change in
muscle mass ranged
f rom 0.04 to 0.49 stan-
dard deviat ions f rom
baseline across the
dif ferent assessment
modalit ies used
The mean change in
muscle mass ranged
f rom 0.09 to 1.01 stan-
dard deviations higher
across the dif ferent
assessment modalit ies
used.
314
(8 studies)
⊕©©©
very low4,5,6,7
Exercise performance -
walking distance
6MWT, ISWT, ESWT
Follow-up: median 6
weeks
The mean change in
distance walked was
21, 36, and 37 metres
f rom baseline across
the dif ferent walking
tests used
The mean change in
distance walked was
35, 9, and 64 me-
tres further across the
dif ferent walking tests
used.
788
(13 studies)
⊕©©©
very low2,7,8,9
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Exercise performance -
peak oxygen uptake
Follow-up: median 6
weeks
The mean change in
peak oxygen uptake
was -0.4 mL/ min f rom
baseline
The mean exercise per-
formance - peak oxy-
gen uptake in the inter-
vent ion groups was 44.
8 mL/ min higher (95%
CI 7.3 lower to 97.0
higher)
109
(4 studies)
⊕⊕©©
low 7,9
* The basis for the assumed risk is the mean change f rom baseline in the control groups. The corresponding risk (and its
95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion
(and its 95% CI).
6M WT: 6-minute walk test; CI: conf idence interval; DEXA: dual energy X-ray absorpt iometry; ESWT: endurance shutt le walk
test; ISWT: incremental shutt le walk test
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and
may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is
likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Downgraded once: the lower 95% CI for the est imate of ef fect was below what would be considered a small ef fect
(standardised mean dif ference 0.2).
2Downgraded once: stat ist ical tests indicated a high degree of heterogeneity; I2 values > 0.5.
3Downgraded once: small populat ion size and lim itat ions in report ing of safety data collect ion.
4Downgraded once: the est imate of ef fect for this outcome was inconsistent across dif ferent assessment modalit ies.
5Downgraded once: either study part icipants or outcome assessors were not blinded, but the outcome being assessed was
non-volit ional.
6Downgraded once: f indings derived f rom computed tomography were f rom a single study.
7Downgraded once: wide variance of point est imates, and inconsistency regarding the direct ion of an ef fect or whether or not
there is an ef fect.
8Downgraded once: the lower 95% CI for the ef fect est imate for the 6MWT was below the established minimally important
dif f erence.
9Downgraded once: either study part icipants or outcome assessors were not blinded, and the outcome being assessed was
volit ional.
B A C K G R O U N D
This review is an update of a previously published review in the
Cochrane Database of Systematic Reviews Issue 1, 2013 on Neu-
romuscular electrical stimulation for muscle weakness in adults
with advanced disease.
Description of the condition
Patients with progressive diseases such as cancer or chronic ob-
structive pulmonary disease (COPD) frequently develop muscle
weakness as a consequence of the disease and its treatment. Pa-
tients often adopt sedentary lifestyles due to limiting symptoms
that can lead to lower limb weakness, which precipitates a down-
ward spiral of disability. Other aetiological factors for skeletal mus-
cle dysfunction, dependent on the disease, include low-grade sys-
temic inflammation, nutritional insufficiency, and/or an imbal-
ance between anabolic and catabolic hormones (Donaldson 2012).
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Muscle weakness impacts adversely on levels of physical func-
tion, independence, and quality of life (Dodson 2011;Man 2009;
Strassburg 2005). Evidence concerning its impact is strongest in
COPD, where lower limb muscle dysfunction has been shown to
directly influence exercise performance and, independent of lung
disease severity, predict healthcare utilisation, in Greening 2015,
and mortality (Donaldson 2012). Aerobic and resistance exer-
cise, when performed regularly, can improve muscle function and
the related clinical consequences (Bausewein 2008; Cramp 2008;
Lacasse 2006). However, the reach of supervised programmes is
limited by issues around time, scheduling, and travel.Whole-body
exercises are also not always accessible to patients who experience
a high symptom burden, or who become breathless at low levels
of exertion (Fischer 2009; Gysels 2007; Maddocks 2009b).
Description of the intervention
In patients who are unable or unwilling to perform conventional
exercise, neuromuscular electrical stimulation (NMES) may be
an alternative method of enhancing lower limb muscle strength.
NMES uses a lightweight, battery-powered stimulator unit which,
via self adhesive electrodes, produces a controlled and comfort-
able contraction and relaxation of the underlying muscles (Dehail
2008). NMES can be used to produce a muscle contraction
equivalent to 20% to 40% of a maximum voluntary contraction
(Maffiuletti 2010), and therefore fulfils the American College of
Sports Medicine’s broader definition of exercise as “a planned,
structured and repetitive bodily movement done to improve or
maintain one ormore components of physical fitness” (Thompson
2010). NMES of the quadriceps muscles can be self administered
at home, unsupervised, and carries a low metabolic load, thus
providing an acceptable therapy to patients living with a high
symptom burden (Sillen 2014b). As a passive treatment, it poten-
tially demands less change in lifestyle than other forms of exercise
(Ambrosino 2004).
How the intervention might work
Studies in people with cardio-respiratory disease have examined
NMES alone and occasionally as an adjunct to other forms of
exercise training. A typical programme consists of 30 to 60 min-
utes of stimulation, generally of the quadriceps with or without
additional lower limb muscles, for example calves, hamstrings,
or glutei, three to five times each week, for four to eight weeks
(Dehail 2008; Roig 2009; Sillen 2009). Programmes appear to be
well tolerated, to lead to similar changes in muscle biochemistry
as other forms of exercise (Dal Corso 2007; Gondin 2011; Nuhr
2004), and are associated with improvements in muscle function,
exercise capacity, and components of quality of life, for example
exertional breathlessness (Maddocks 2009a; Neder 2002; Nuhr
2004; Vivodtzev 2006).
Why it is important to do this review
Despite these promising findings, clinical studies of NMES have
generally been small and of variable methodological quality. Fur-
thermore, where findings are pooled they tend to be disease spe-
cific, so overall estimates of effect for NMES lack power and preci-
sion. This updated review aimed to provide a comprehensive syn-
thesis of the evidence base regarding the use of NMES for muscle
weakness in adults with advanced disease.
O B J E C T I V E S
Primary objective: to evaluate the effectiveness of NMES on
quadriceps muscle strength in adults with advanced disease. Sec-
ondary objectives: to examine the safety and acceptability of
NMES, and its effect on peripheral muscle function (strength
or endurance), muscle mass, exercise capacity, breathlessness, and
health-related quality of life.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) with a parallel,
single-stage, or cross-over design, including studies using minimi-
sation, or with a quasi-randomised allocation in cases where allo-
cation concealment was described.
Types of participants
Participants were adults with advanced diseases where muscle loss
and weakness is common, that is cancer, COPD, chronic heart
failure (CHF), or HIV/AIDS (Evans 2008; Muscaritoli 2010).
The inclusion criteria for advanced disease were as follows. Partic-
ipants with cancer should have locally advanced or metastatic dis-
ease and should not be receiving or scheduled for anticancer treat-
ment with curative intent. Participants with COPD should have a
forced expiratory volume in one second (FEV1) of less than 50%
predicted and be categorised as stage III or IV by Global Initiative
for Chronic Obstructive Lung Disease (GOLD) spirometric crite-
ria (GOLD 2005). Participants with CHF should have New York
Heart Association stage III or IV disease (NYHA 1994), and par-
ticipants with AIDS should be categorised as clinical stage 3 or 4
by theWorldHealthOrganization (WHO) criteria (WHO2007).
The cutoff point for including individual participant groups was
50%, that is at least half of the study population must fall within
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the definitions outlined above. Participants may be studied in any
setting. We did not include studies relating to participants with
conditions not regarded as progressive, refractory to treatment and
advanced, or applying NMES in the presence of recognised con-
tra-indications, for example local malignancy.
Types of interventions
We included studies examining a programme of NMES (more
than one session) offered as a sole intervention or as an adjuvant
to another form of exercise. Stimulation could be applied to the
quadriceps with or without additional lower limb muscle groups,
for example hamstrings, gastrocnemius, glutei. We expected pro-
grammes to vary in terms of stimulation frequency (Hz), pulse type
and width (µs), duty cycle (the proportion of time the intervention
is ‘active’, usually expressed as a percentage), session length (min),
and frequency (sessions/week) and overall programme duration
(weeks). We did not include studies examining the acute effects
of NMES following a single session. We used no restrictions on
the site of stimulation or parameters used. Interventions could be
compared to either an inactive control (e.g. no treatment, placebo,
or sham NMES), or an active control such as an alternative form
of exercise.
Types of outcome measures
Primary outcomes
1. Quadriceps muscle strength assessed immediately following
a programme of NMES.
Secondary outcomes
1. Adherence to prescribed programmes.
2. Occurrence of adverse events.
3. Muscle strength, endurance, and mass.
4. Exercise performance.
5. Breathlessness.
6. Health-related quality of life.
Search methods for identification of studies
Electronic searches
The search for the original review was performed on 1 July 2012.
The search period for this update was from 1 July 2012 to 6
January 2016. We searched the following electronic databases for
this update:
• Cochrane Central Register of Controlled Trials
(CENTRAL) Issue 12 of 12, 2015 (the Cochrane Library);
• Cochrane Database of Systematic Reviews (CDSR) Issue 12
of 12, 2015 (the Cochrane Library);
• *Database of Abstracts of Reviews of Effects (DARE), Issue
1 of 4, 2015 (the Cochrane Library);
• MEDLINE (OVID) July 2012 to 5 January 2016;
• Embase (OVID) July 2012 to 5 January 2016;
• CINAHL (EBSCO) July 2012 to 5 January 2016;
• PsycINFO (OVID) 2012 to December week 5 2015;
• British Nursing Index July 2012 to 5 January 2016;
• Web of Science July 2012 to 5 January 2016.
*DARE has not been updated since March 2015. See Appendix 1
for details of the search strategies.
Searching other resources
In the original review we checked reference lists of identi-
fied articles and articles citing all retrieved studies, relevant
editorials, and reviews (Ambrosino 2004; Ambrosino 2008;
Dehail 2008; Dourado 2004; Larsen 2004; Roig 2009; Sillen
2009; Vivodtzev 2009), websites (www.ifess.org, www.srr.org.uk,
www.electrotherapy.org), and textbooks (Baker 2000; Robertson
2006; Skinner 2005) for further studies.
For this update, we searched the metaRegister of controlled tri-
als (mRCT) (www.controlled-trials.com/mrct), ClinicalTrials.gov
(www.clinicaltrials.gov), and the WHO International Clini-
cal Trials Registry Platform (ICTRP) (apps.who.int/trialsearch/)
on 6 January 2016 to identify additional completed or on-
going studies. We reviewed the electrotherapy database (
www.electrotherapy.org), bibliographies of any randomised tri-
als, and review articles identified, and contacted the authors and
known experts in the field to identify additional published or un-
published data. We also made contact with corresponding authors
of retrieved studies and researchers known to be active in this topic
area to learn of any unpublished data or grey literature arising
from meetings or conference proceedings. We used no language
restriction in the selection of studies.
Data collection and analysis
Selection of studies
We merged studies identified by the search strategy, removed any
duplicates, and two review authors (SJ, MM) independently as-
sessed the titles and abstracts for relevance. We reviewed abstracts
of potentially eligible studies, and where any reference was made
to NMES we obtained full texts. In cases where abstracts were not
available and the study could not be excluded on the basis of its
title, we obtained full texts. Two review authors (SJ, MM) inde-
pendently assessed the full texts of potentially relevant studies for
compliance with the review eligibility criteria. Review authors re-
solved any disagreements by discussion. Where required, we made
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requests to study authors for further information until a consensus
regarding study eligibility was reached.
Data extraction and management
We (SJ, WG, AW, MM) extracted data from included studies to
summarise study methods and bias (study design, sequence gen-
eration, allocation sequence concealment, blinding), participants
(number, age, sex, ethnicity, diagnosis, disease severity, setting),
and interventions (target muscle group(s), programme frequency,
pulse type and width, duty cycle, session length and frequency,
and overall programme duration). We recorded adherence to the
prescribed programme (either self reported or objective) and the
occurrence of any adverse events.
Outcome data collected at baseline, and immediately following a
NMES programme or at first follow-up, included:
• quadriceps muscle strength, either isometric or isotonic,
generally assessed using myometry and a measure of force (e.g. in
kilograms (kg) or Newton metres (Nm));
• other muscle strength or muscle endurance, with endurance
generally assessed as time or number of repetitions to a specified
decline in muscle performance;
• muscle mass, generally assessed by anthropometry or
imaging as volume (cm3) or cross-sectional area, typically
measured at the midpoint of the muscle (cm2);
• maximal and submaximal exercise capacity, generally
assessed by a walking or cycling test and a measure of oxygen
uptake (mL/min) or performance, e.g. distance walked in metres
(m);
• breathlessness, generally assessed according to intensity on a
numerical or categorical scale, with a higher score representing
more severe breathlessness;
• health-related quality of life, generally assessed on a
numerical or categorical scale with a higher score representing a
better quality of life.
Two review authors independently extracted data and resolved any
disagreements by discussion until a consensus was reached.
Assessment of risk of bias in included studies
Two review authors (SJ,MM orWG) independently assessed each
study for risk of bias using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Weobtained information to aid this assessment from study reports,
protocols, published comments, and personal contact with study
authors. Thereafter, we made a judgement as to the level of risk of
bias for that domain. We assessed the following for each study.
• Random sequence generation (checking for possible
selection bias). We assessed the method used to generate the
allocation sequence as: low risk of bias (any truly random
process, e.g. random number table, computer random number
generator); unclear risk of bias (method used to generate
sequence not clearly stated).
• Allocation concealment (checking for possible selection
bias). The method used to conceal allocation to interventions
prior to assignment determines whether intervention allocation
could have been foreseen in advance of, or during, recruitment,
or changed after assignment. We assessed the methods as: low
risk of bias (e.g. telephone or central randomisation,
consecutively numbered, sealed, opaque envelopes); unclear risk
of bias (method not clearly stated).
• Blinding of participants and personnel (checking for
possible performance bias). We assessed the methods used to
blind study participants and personnel from knowledge of which
intervention a participant received. We assessed methods as: low
risk of bias (study stated that it was blinded and described the
method used to achieve blinding); unclear risk of bias (study
stated that it was blinded but did not provide an adequate
description of how this was achieved). We considered studies
that were not double-blind to have a high risk of bias.
• Blinding of outcome assessment (checking for possible
detection bias). We assessed the methods used to blind study
participants and outcome assessors from knowledge of which
intervention a participant received. We assessed the methods as:
low risk of bias (study had a clear statement that outcome
assessors were unaware of treatment allocation, and ideally
described how this was achieved); unclear risk of bias (study
stated that outcome assessors were blind to treatment allocation
but lacked a clear statement on how this was achieved). We
would often but not always exclude studies where outcome
assessment was not blinded; if included, we considered them as
having a high risk of bias.
• Incomplete outcome data (checking for possible attrition
bias due to the amount, nature, and handling of incomplete
outcome data). We assessed the methods used to deal with
incomplete data as: low risk (less than 10% of participants did
not complete the study and/or ‘baseline observation carried
forward’ analysis was used); unclear risk of bias (used ’last
observation carried forward’ analysis); high risk of bias (used
’completer’ analysis).
• Selective reporting (checking for possible reporting bias).
We assessed studies for selective outcome reporting using the
following judgements: low risk of bias (study protocol available
and all prespecified primary outcomes of interest adequately
reported or study protocol not available but all expected primary
outcomes of interest adequately reported or all primary
outcomes numerically reported with point estimates and
measures of variance for all time points); unclear risk of bias
(insufficient information provided to permit a judgement of low/
high risk of bias); or high risk of bias (incomplete reporting of
prespecified primary outcomes or point estimates and measures
of variance for one or more primary outcome not reported
numerically (e.g. graphically only) or one or more primary
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outcomes reported using measurements, analysis methods, or
subsets of data that were not prespecified or one or more
reported primary outcomes were not prespecified or results for a
primary outcome expected to have been reported were excluded).
• In this updated review we also considered study size
(checking for possible biases confounded by small size). We
assessed studies as being at low risk of bias (equal to or more than
200 participants per treatment arm); unclear risk of bias (50 to
199 participants per treatment arm); high risk of bias (fewer than
50 participants per treatment arm).
Measures of treatment effect
The key comparison of interest for any meta-analysis was NMES
versus any study control intervention, including no treatment,
placebo, or an active comparator. We presented treatment effect
sizes using appropriate metrics. We analysed outcomes as contin-
uous data when possible. We expressed the size of treatment ef-
fect using the mean difference (MD) (where all studies utilised
the same measurement scale) or the standardised mean difference
(SMD) (where studies used different scales). In order to aid in-
terpretation of the pooled effect size for quadriceps strength, our
primary outcome, we back-transformed the SMD value to a kilo-
gram format on the basis of the mean standard deviation (SD)
from trials using this measurement scale. We plotted the results of
each study’s available data as point estimates with corresponding
95% confidence intervals (CIs) using forest plots. If included trials
demonstrated clinical homogeneity, we performed meta-analysis
using an inverse variable fixed-effect model to estimate the overall
direction, size, and consistency of a strengthening effect on the
quadriceps muscles from NMES immediately postprogramme. If
included trials demonstrated clinical heterogeneity we used a ran-
dom-effects model. For outcomes where we consideredmeta-anal-
ysis not appropriate, we described the findings from individual
studies.
Unit of analysis issues
All included trials randomised participants at the individual par-
ticipant level. We planned to include data from all study groups
when participants had been allocated to one of multiple NMES
groups, using the same control group data for both comparisons.
We planned to enter cross-over trials into a meta-analysis when it
was clear that data were free from carry-over effects, and to com-
bine the results of cross-over trials with those of parallel trials by
imputing the postprogramme between-group correlation coeffi-
cient from an included trial, if individual participant data were
available. However, as we did not identify any cross-over trials that
met the inclusion criteria of this review, issues concerning them
did not arise.
Dealing with missing data
In cases where there were missing data or insufficient data to per-
form meta-analysis, we attempted to contact the study authors of
included studies. If study authors only presented data in graphical
form, we did not attempt to extract the data from the figures.
Assessment of heterogeneity
We evaluated the included trials for clinical homogeneity regard-
ing study population, NMES and control interventions, timing of
follow-up, and outcome measurement. For trials that were suffi-
ciently clinically homogenous to pool, we formally explored het-
erogeneity using the Chi2 test to investigate the statistical signif-
icance of any heterogeneity, and the l2 statistic to estimate the
amount of heterogeneity across trial conditions and its impact on
themeta-analysis (Higgins 2002; Higgins 2003). If considerable (I
2 greater than 50%) or substantial clinical heterogeneity (I2 greater
than 75%) was confirmed, we performed a random-effects model
or separate fixed-effect model calculation to estimate a strength-
ening effect from NMES for each subgroup.
Assessment of reporting biases
We considered the possible influence of small-study/publication
biases on review findings as part of our ’Risk of bias’ assessment
and GRADE assessments of the quality of the evidence. Where
sufficient data are available, we may include visual or statistical
analyses of reporting bias in future updates of thisCochrane review.
Data synthesis
We grouped extracted data according to intervention, compara-
tor, and outcome. Regarding interventions, we pooled data from
studies that investigated NMES as single therapy and alongside
other treatments together. For multi-arm studies with multiple
NMES interventions, we considered each intervention separately.
Regarding comparators, we pooled data across trials with a no-
treatment, placebo, and active comparator together. We reported
the outcome of the ’Risk of bias’ assessment but included all data
in our analyses. Where we found inadequate data to support sta-
tistical pooling, we described a narrative synthesis of the overall
evidence.
Quality of the evidence
Two review authors (SJ, MM) independently rated the quality
of the evidence for each outcome using the GRADE system to
rank the quality of the evidence employing GRADEpro GDT
(GRADEpro GDT 2015). The GRADE approach uses five con-
siderations (study limitations, consistency of effect, imprecision,
indirectness, and publication bias) to assess the quality of the body
of evidence for each outcome. The GRADE system uses the fol-
lowing criteria for assigning grade of evidence.
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• High: further research is very unlikely to change our
confidence in the estimate of effect.
• Moderate: further research is likely to have an important
impact on our confidence in the estimate of effect and may
change the estimate.
• Low: further research is very likely to have an important
impact on our confidence in the estimate of effect and is likely to
change the estimate.
• Very low: any estimate of effect is very uncertain.
We decreased grade if:
• serious (-1) or very serious (-2) limitation to study quality;
• important inconsistency (-1);
• some (-1) or major (-2) uncertainty about directness;
• imprecise or sparse data (-1);
• high probability of reporting bias (-1).
We included a ’Summary of findings’ table to present the main
findings. In particular, we included key information concerning
the quality of the evidence, the magnitude of effect of the inter-
ventions examined, and the sum of available data on quadriceps
muscle strength, adverse events, muscle mass, and exercise perfor-
mance.
Subgroup analysis and investigation of heterogeneity
For outcomes where sufficient data were available, we used de-
scriptive comparisons to consider differences betweenprogrammes
that involved stimulating the quadriceps alone or in combination
with one or more additional muscle groups, for programmes up
to or over six weeks overall duration, and in populations with and
without COPD, as the aetiology driving muscle dysfunction may
be expected to be different.
Sensitivity analysis
To examine the robustness of the primary analysis of an effect on
quadricepsmuscle strength, we completed sensitivity analyses after
removing studies where participants or outcome assessors were not
blinded to the study treatment allocation, and studies in which
NMES was compared to an active intervention such as resistance
training.
R E S U L T S
Description of studies
We included a total of 18 studies in this update, adding seven new
studies since the previous version (Akar 2015; Greening 2014;
Maddocks 2013; Maddocks 2016a; Sillen 2014a; Tasdemir 2015;
Vieira 2014).
Results of the search
Our initial search for the previous review yielded 11 eligible studies
(Figure 4) across patient groups with COPD (Abdellaoui 2011;
Bourjeily-Habr 2002; Dal Corso 2007; Nápolis 2011; Neder
2002; Vivodtzev 2006; Vivodtzev 2012; Zanotti 2003), chronic
heart failure (Nuhr 2004; Quittan 2001), and thoracic cancer
(Maddocks 2009a).
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Figure 4. Study flow diagram.
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Searches for this update yielded 163 separate new citations, and we
retrieved 12 full texts (Figure 4). Seven studies met the eligibility
criteria across patient groups with COPD (Akar 2015; Maddocks
2016a; Sillen 2014a; Tasdemir 2015; Vieira 2014), chronic respi-
ratory disease (Greening 2014), and thoracic cancer (Maddocks
2013). Five studies were two-arm RCTs. Two studies were three-
arm RCTs (Akar 2015; Sillen 2014a), and we considered data on
both NMES interventions studied for meta-analyses. We identi-
fied no new studies that recruited participants with HIV/AIDS.
Included studies
Participants
Overall, the 18 included studies related to 933 participants with
four different conditions: COPD: 13 studies, 403 participants
(Abdellaoui 2011; Akar 2015; Bourjeily-Habr 2002; Dal Corso
2007;Maddocks 2016a; Nápolis 2011; Neder 2002; Sillen 2014a;
Tasdemir 2015; Vieira 2014; Vivodtzev 2006; Vivodtzev 2012;
Zanotti 2003); chronic respiratory disease: 1 study, 389 partici-
pants (Greening 2014); chronic heart failure: 2 studies, 76 partici-
pants (Nuhr 2004; Quittan 2001); and thoracic cancer: 2 studies,
65 participants (Maddocks 2009a; Maddocks 2013). The mean
age of participants ranged from 53 to 71 years, and overall there
was a male preponderance (n = 505/54%). Some studies tar-
geted patients with predetermined body mass index (Abdellaoui
2011; Vivodtzev 2006),muscle weakness (Sillen 2014a; Vivodtzev
2006), or level of breathlessness (Dal Corso 2007; Greening 2014;
Nápolis 2011;Neder 2002; Sillen 2014a; Vieira 2014), whilst oth-
ers had broad inclusion criteria (e.g. Bourjeily-Habr 2002; Nuhr
2004). Common exclusion criteria included locomotor or neuro-
logical conditions that would affect ability to exercise, or features
that could restrict the use of NMES, such as an implantable car-
diac pacemaker. For more detailed information including eligibil-
ity criteria, see the Characteristics of included studies table.
Interventions and controls
NMES interventions were offered at home after an initial pe-
riod of teaching, with the exception of five studies with inter-
ventions offered following a period of acute critical illness, which
were offered to inpatients (Abdellaoui 2011; Akar 2015; Greening
2014; Vivodtzev 2006; Zanotti 2003). All programmes targeted
the quadriceps either alone or with additional muscle groups in-
cluding the hamstrings (Abdellaoui 2011; Bourjeily-Habr 2002;
Nuhr 2004; Quittan 2001), calves (Bourjeily-Habr 2002; Sillen
2014a; Vivodtzev 2012), glutei (Zanotti 2003), and deltoids (Akar
2015). NMES was offered alone in all but seven studies, where
NMES was offered as part of a more comprehensive rehabilitation
programme (Akar 2015; Greening 2014; Sillen 2014a; Tasdemir
2015; Vieira 2014; Vivodtzev 2006; Zanotti 2003).
Stimulation parameters and programme characteristics varied con-
siderably among studies, with median (range) values of: stimu-
lation frequency 50 (15 to 75) Hz, pulse duration 400 (200 to
700) µs, target duty cycle 33 (13 to 75) %, session length 30
(18 to 240) minutes, session frequency 5 (2 to 7) times each
week, and programme duration 6 (4 to 11) weeks. In all stud-
ies, stimulation amplitude was reported to be set to elicit a visible
or palpable muscle contraction within the participant’s tolerance
and increased over the course of the programme. Five studies re-
ported initial training amplitudes (range 10 to 57 maximum am-
plitude) (Abdellaoui 2011; Akar 2015; Bourjeily-Habr 2002; Dal
Corso 2007;Maddocks 2016a), which are of limited value without
knowledge of the (variable) assumed skin resistance of the stimu-
lation unit used. Where the level of contraction was expressed ac-
cording to participants’ maximum voluntary contraction, starting
values ranged from 25% to 30% (Nuhr 2004; Quittan 2001).
Outcome measures
Thirteen studies assessed quadriceps muscle strength using fixed,
in Bourjeily-Habr 2002, Dal Corso 2007, Greening 2014,
Maddocks 2009a, Maddocks 2013, Maddocks 2016a, Nápolis
2011, Neder 2002, Quittan 2001, Sillen 2014a, Vivodtzev 2006,
Vivodtzev 2012, or hand-held, in Abdellaoui 2011, dynamome-
try. Two studies assessed peripheral muscle strength globally using
a physician-rated categorical scale (Akar 2015; Zanotti 2003), and
one study used one-repetitionmaximumby freeweights (Tasdemir
2015).
Strength assessments for other stimulated muscle groups were lim-
ited to the hamstrings (Bourjeily-Habr 2002;Quittan 2001). Four
studies used fatigue-inducing constant load protocols were used to
examine quadriceps endurance (Neder 2002; Quittan 2001; Sillen
2014a; Vivodtzev 2012). Body composition assessments used to
assess themass of peripheral muscles, usually of the thigh, included
anthropometry (Vieira 2014; Vivodtzev 2006), dual energy X-
ray absorptiometry (DEXA) (Dal Corso 2007; Maddocks 2013),
ultrasonography (Maddocks 2016a), and computed tomography
(Quittan 2001; Vivodtzev 2012). Maximal and submaximal exer-
cise capacity were assessed using cycle ergometry cardiopulmonary
exercise testing (Nápolis 2011; Neder 2002; Nuhr 2004; Sillen
2014a; Vieira 2014), 6-minute walk test (6MWT) (Abdellaoui
2011; Dal Corso 2007; Maddocks 2016a; Nápolis 2011; Nuhr
2004; Sillen 2014a; Vieira 2014; Vivodtzev 2006), incremen-
tal shuttle walk test (ISWT) (Bourjeily-Habr 2002; Greening
2014; Tasdemir 2015), or endurance shuttle walk test (ESWT)
(Greening 2014; Maddocks 2009a; Tasdemir 2015; Vivodtzev
2012).
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Other objective measures included performance in various lower
limb functional tasks: sit to stand (Quittan 2001; Tasdemir 2015),
the number of days for participants on an intensive care unit to
be transferred from bed to chair (Akar 2015; Zanotti 2003), and
physical activity level assessed using an accelerometer (Maddocks
2009a; Maddocks 2013; Maddocks 2016a). Eight studies re-
ported on breathlessness either as part of a quality of life assess-
ment (Maddocks 2016a; Neder 2002; Sillen 2014a; Vivodtzev
2006), the Medical Research Council breathlessness scale (Sillen
2014a; Tasdemir 2015), or at an equivalent workload during an
exercise test using the Borg, in Bourjeily-Habr 2002, or modi-
fied Borg Rating of Perceived Exertion scale (Vivodtzev 2012).
Ten studies reported quality of life using different assessment
tools: St George’s Respiratory Disease Questionnaire (SGRQ)
(Greening 2014; Maddocks 2016a; Sillen 2014a; Tasdemir 2015;
Vieira 2014) 36-Item Short FormHealth Survey (SF-36) (Quittan
2001), Chronic Respiratory Questionnaire (Maddocks 2016a;
Neder 2002; Sillen 2014a), Minnesota Living with Heart Fail-
ure Questionnaire (Nuhr 2004), Maugeri Foundation Respiratory
Failure Questionnaire (Vivodtzev 2006), and European Organi-
sation for the Research and Treatment of Cancer Quality of Life
Core 30 (EORTC QLQ-C30) (Maddocks 2013).
Excluded studies
We excluded a total of 75 studies in this update (71 in the original
review, and four in this update). The previous review did not
correctly list all 71 excluded studies, which we have now corrected
in this update.
In the previous review, studies requiring discussion were excluded,
for example on the basis of not including participants with ad-
vanced disease (Sumin 2009a), failing to meet the review criteria
for the proportion of participants with advanced disease (equal to
or greater than 50%) (Banerjee 2009; Deley 2005; Dobsák 2006a;
Harris 2003; LeMaitre 2006), randomising at the level of the limb
rather than the participant, with NMES applied to one leg and
the same participant’s other leg being used as a control (Giavedoni
2010), or usingmagnetic rather than electrical stimulation to elicit
muscle contractions (Bustamante 2010). In this update we ex-
cluded one study because it was not possible to define advanced
disease inmultiple sclerosis (Coote 2015), one study because it did
not use a randomised design (Tasdemir 2015), one study because
it was a substudy examining the acute effects of a single session of
NMES (Sillen2014b), and afinal study because it randomised par-
ticipants to receive one of two different NMES programmes, but
did not include a comparator group (Chaplin 2013). For further
details on all excluded studies, see the Characteristics of excluded
studies table.
Risk of bias in included studies
See Characteristics of included studies, Figure 5, and Figure 6.
Figure 5. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 6. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
All 18 studies were randomised to minimise selection bias. In
nine studies the description of sequence generation was ade-
quate, for example with studies using block-wise randomisation,
in Abdellaoui 2011, Maddocks 2009a, Maddocks 2013, Quittan
2001, or minimisation (Maddocks 2016a), and so we judged them
to be at low risk of bias for this domain. An adequate description
of sequence generation was not provided for the remaining nine
studies, and we judged them to be at unclear risk of bias for this
domain.
Eleven studies described themethods used to conceal group alloca-
tion, using sealed, opaque envelopes (Abdellaoui 2011;Maddocks
2009a; Nuhr 2004; Tasdemir 2015), web-based system (Greening
2014; Maddocks 2016a), telephone system (Maddocks 2013), or
secure locked codes (Neder 2002; Quittan 2001; Sillen 2014a;
Vieira 2014). We therefore judged these studies to be at low
risk of bias for this domain. In seven studies there was insuffi-
cient information to assess allocation concealment (Akar 2015;
Bourjeily-Habr 2002; Dal Corso 2007; Nápolis 2011; Vivodtzev
2006; Vivodtzev 2012; Zanotti 2003), and we judged these stud-
ies to be at unclear risk of bias. We did not identify any studies at
high risk of selection bias.
Blinding
Seven studies used a placebo model of NMES as a control to blind
participants, and we judged them to be at low risk of performance
bias. Placebo models generally used the same physical setup but
restricted the stimulation output, in Abdellaoui 2011, Maddocks
2016a,Nuhr 2004, and/or reduced stimulation parameters, inDal
Corso 2007, Maddocks 2016a, Nápolis 2011, Tasdemir 2015,
Vivodtzev 2012, to avoid any visible or palpable muscle contrac-
tion. Two studies used a sham model with no stimulator output
(Bourjeily-Habr 2002; Vieira 2014), and we judged the risk of bias
to be unclear as there would have been a clear difference in the ex-
perience of NMES and control interventions. No study reported
on the effectiveness of participant blinding.Where no shammodel
was used, studies recommended that participants continue with
their usual activities of daily living whilst keeping a diary (Quittan
2001), undertake other forms of rehabilitation, for example ac-
tive limbmobilisations, light walking (Akar 2015;Greening 2014;
Sillen 2014a; Vivodtzev 2006; Zanotti 2003), or offered no in-
tervention (Maddocks 2009a; Maddocks 2013; Neder 2002). We
therefore judged these studies to be at high risk of performance
bias.
Blinding of outcome assessors was adequately described in
eight studies (Akar 2015; Bourjeily-Habr 2002; Greening 2014;
Maddocks 2016a; Nápolis 2011; Quittan 2001; Sillen 2014a;
Zanotti 2003), and we juddged these studies to be at low risk of
detection bias. Five studies did not blind the outcome assessor
(Abdellaoui 2011; Dal Corso 2007; Maddocks 2009a, Maddocks
2013; Tasdemir 2015), and we judged them to be at high risk of
bias for this domain. The remaining five studies provided insuffi-
cient information to assess blinding, and we judged them to be at
unclear risk of detection bias.
Incomplete outcome data
Overall, 93 out of 933 randomised participants (10%) withdrew
from a study prior to the postprogramme assessment. In one study,
three participantswithdrew from the intervention armdue tomus-
cle discomfort (Maddocks 2013), and in another study there was
an increased number of exacerbations in the control arm (Vieira
2014). We therefore judged both of these studies to have a high
risk of attrition bias. A further study reported participants declin-
ing due to severe disability (Sillen 2014a), and we judged the risk
of attrition bias to be unclear. In the remaining 15 studies, attri-
tion was similar across NMES and control groups, and missing
outcome information was generally due to technical error (e.g.
Maddocks 2009a; Nápolis 2011). We judged the risk of attrition
bias for these studies to be low.
Selective reporting
We found evidence of selective reporting in one study report in
which a lack of strengthening effect of NMES was presented as
evidence of safety (Nuhr 2004), and therefore judged the risk of
reporting bias to be high. We judged the remaining 17 studies to
be at low risk of detection bias.
Other potential sources of bias
Seventeen studies had fewer than 50 participants per study arm,
and as such we judged these studies to have a high risk of bias
due to small study size. We judged the remaining study to have
an unclear risk of bias relating to study size (Greening 2014) (see
Characteristics of included studies, Figure 5, and Figure 6).
Effects of interventions
See: Summary of findings for the main comparison
Neuromuscular electrical stimulation (NMES) versus control for
adults with advanced disease for muscle weakness
Primary outcome
Quadriceps muscle strength
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Twelve studies (781 participants) assessed quadriceps strength us-
ing dynamometry (Abdellaoui 2011; Bourjeily-Habr 2002; Dal
Corso 2007; Greening 2014; Maddocks 2009a; Maddocks 2013;
Maddocks 2016a; Nápolis 2011; Neder 2002; Quittan 2001;
Sillen2014a;Vivodtzev 2006;Vivodtzev 2012). Therewas consid-
erable heterogeneity among studies (I2 = 72%), and we thus used a
random-effects model for the pooled analysis (Analysis 1.1; Figure
1). Compared to control groups, NMES significantly improved
quadriceps strength by a standardised mean difference (SMD) of
0.53 (95% confidence interval (CI) 0.19 to 0.87), which would be
considered a moderate effect size (Cohen 1988). Sensitivity analy-
ses removing studies where participants (SMD 0.54, 95% CI 0.11
to 0.98) or outcome assessors (SMD 0.45, 95% CI 0.07 to 0.84)
were not blinded did not affect the overall findings. Removing a
study where NMES was compared to a resistance training inter-
vention, Sillen 2014a, increased the point estimate for effective-
ness (SMD 0.68, 95% CI 0.28 to 1.09) but did not alter hetero-
geneity (I2 = 72%). In subgroup analyses, the overall direction of a
strengthening effect was similar between studies involving partic-
ipants with COPD (SMD 0.39, 95% CI 0.03 to 0.76; I2 = 57%)
and without (SMD 1.23, 95% CI 0.23 to 2.24; I2 = 72%). Clini-
cal heterogeneity was too high to compare by subgroups according
to the muscle group(s) stimulated or the overall programme dura-
tion. We judged the quality of the evidence for quadriceps muscle
strength to be low. We downgraded the quality of the evidence by
one level for inconsistency due to the high degree of heterogeneity
between studies, I2 greater than 0.5. Regarding imprecision, the
lower 95% CI for the effect estimate was below what is considered
to be a small effect size (SMD 0.2), so we decided to downgrade
on this basis (see Summary of findings for the main comparison).
Secondary outcomes
Adherence to prescribed programmes
Where reported, rates of adherence with the recommended
programme were generally high, with mean values of 95%
(Bourjeily-Habr 2002), 97% (Abdellaoui 2011; Quittan 2001),
100% (Nuhr 2004; Vivodtzev 2006), and a median of 80%
(Maddocks 2009a). One study described participants as “compli-
ant” (Vivodtzev 2012), and another as “excellent” (Neder 2002).
In the only “pragmatic” study, 61% of participants reported daily
adherence to the home-based component of a programme utilising
NMES alongside other interventions (Greening 2014). Four stud-
ies noted that participants with COPDwere able to commence, in
Greening 2014, or continue, in Abdellaoui 2011, Nápolis 2011,
Neder 2002, to use NMES during an acute exacerbation of dis-
ease. We judged the quality of the evidence for adherence to be
low. We downgraded the evidence due to indirect assessment of
adherence in most studies, which was by self report, and incon-
sistency in adherence estimates from each study, given the wide
range (61% to 97%).
Occurrence of adverse events
No serious adverse events were reported. Nineteen of the 518 par-
ticipants (4%) allocated to NMES across four studies reported
muscle discomfort following NMES during the initial few days of
a programme (Bourjeily-Habr 2002;Maddocks 2009a;Maddocks
2013; Quittan 2001). A further two participants (less than 1%)
from one study reported persistent erythema, which was con-
sidered possibly related to use of adhesive electrodes (Maddocks
2016a). All other studies stated that no adverse events occurred.
For both serious adverse events and adverse events, we judged the
quality of the evidence to be moderate. We downgraded the ev-
idence due to the small overall sample size and limitations in re-
porting of safety data collection.
Muscle strength, endurance, and mass
Hamstring muscle strength increased following NMES in two
studies (Bourjeily-Habr 2002; Quittan 2001), with statisti-
cally significant differences favouring NMES compared to con-
trol groups. Peripheral muscle strength was increased following
NMES, as compared to the control condition, in one study
(Zanotti 2003), but not in another (Akar 2015). A statisti-
cally significant improvement in quadriceps endurance following
NMES, as compared to the control condition, was reported in all
three studies assessing this outcome (Neder 2002; Quittan 2001;
Vivodtzev 2012). We judged the quality of the evidence for these
outcomes to be low. We downgraded the quality of the evidence as
we deemed studies to have a high risk of performance or detection
bias, and point estimates varied widely.
Eight studies (314 participants) assessed quadriceps muscle mass
using either anthropometry (Vieira 2014; Vivodtzev 2006),
DEXA scan (Dal Corso 2007; Maddocks 2013; Sillen 2014a), ul-
trasound (Maddocks 2016a), or computed tomography (Quittan
2001; Vivodtzev 2012). Overall, an improvement in muscle mass
was observed following a NMES programme. The detected effect
appeared dependent on the assessment modality used; there was
no evidence of effect in studies using anthropometry or DEXA,
though moderate to large effects sizes (SMD) observed in studies
using ultrasound 0.82 (95% CI 0.26 to 1.39) or computed to-
mography 1.01 (95% CI 0.42 to 1.60) (Analysis 1.2; Figure 3).
We judged the quality of the evidence for muscle mass to be very
low. We deemed studies to have a high risk of bias where partic-
ipants or outcome assessors, or both were not blinded to group
allocation, and there was inconsistency of results according to as-
sessment modality, wide variation of point estimates, and incon-
sistency regarding the direction of an effect or whether or not an
effect was present. Findings derived from computed tomography
were from a single study (see Summary of findings for the main
comparison).
Exercise performance
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Seven studies (317 participants) used the 6MWT as an outcome
measure (Abdellaoui 2011;Maddocks 2016a;Nápolis 2011;Nuhr
2004; Sillen 2014a; Vieira 2014). The overall mean difference
(MD) for NMES compared to control was 35 m (95% CI 14
to 56; P = 0.001). Three studies (434 participants) used the
ISWT (Bourjeily-Habr 2002; Greening 2014; Tasdemir 2015),
and four studies (452 participants) used the endurance shuttle
walk test (ESWT) (Greening 2014; Maddocks 2009a; Tasdemir
2015; Vivodtzev 2012). There was no statistically significant effect
of NMES compared to control group in these studies: ISWT 9 m
(95%CI -35 to 52; P = 0.69); ESWT 64m (95%CI -18 to 146; P
= 0.12) (Analysis 1.3; Figure 2). Six studies (141 participants) as-
sessed peak oxygen uptake using progressive cardiopulmonary ex-
ercise testing with cycle ergometry (Bourjeily-Habr 2002; Nápolis
2011; Neder 2002; Nuhr 2004; Vieira 2014). There was no sig-
nificant difference in peak oxygen uptake following use of NMES
compared to control conditions (MD 44.82 mL/min, 95% CI -
7.3 to 97.0; P = 0.09) (Analysis 1.3; Figure 2).We judged the over-
all quality of the evidence for exercise performance to be very low
to low. We deemed studies to have a high risk of bias where par-
ticipants or outcome assessors, or both were not blinded to group
allocation, and there was a high degree of heterogeneity between
studies (I2 greater than 0.5) and inconsistency regarding whether
or not an effect was present (see Summary of findings for the main
comparison).
Breathlessness
Self reported breathlessness duringdaily life significantly improved
following NMES in two of four studies that used quality of life
questionnaires containing “dyspnoea”, in Neder 2002, or “dysp-
noea in daily tasks”, in Vivodtzev 2006, domains. Two studies that
assessed disability due to breathlessness using theMedical Research
Council breathlessness scale found no differences in scores follow-
ing NMES versus control (Sillen 2014a; Tasdemir 2015). Breath-
lessness at an equivalent workload during a walking test was sig-
nificantly reduced following NMES in one study (Bourjeily-Habr
2002), though it remained unchanged in another study (Vivodtzev
2012). Given the very limited data, we judged the quality of the
evidence for breathlessness to be very low.
Health-related quality of life
There was inadequate information to support statistical pool-
ing. Most studies reported no significant differences following
NMES as compared to control in either quality of life domains or
overall scores, or both using the Chronic Respiratory Question-
naire (Maddocks 2016a; Sillen 2014a), EQ-5D index (Maddocks
2016a), EORTCQLQ-C30 (Maddocks 2013),Minnesota Living
with Heart Failure Questionnaire (Nuhr 2004), SGRQ (Greening
2014; Maddocks 2016a; Sillen 2014a; Tasdemir 2015), or SF-36
(Quittan 2001). One study reported a significant between-group
difference, favouring NMES, in quality of life as assessed by the
Chronic Respiratory Questionnaire, which arose primarily from
an effect in the “dyspnoea” domain (Neder 2002). Similarly, an-
other study reported a significant between-group difference in the
SGRQ favouring NMES, which arose from the “activity” domain
(Vieira 2014). One further study reported a significant between-
group difference in the “dyspnoea in daily tasks” domain of the
Maugeri Foundation Respiratory Failure Questionnaire in favour
of NMES (Vivodtzev 2006), but the total score was not signifi-
cantly different between groups. Given the very limited data, we
judged the quality of the evidence for health-related quality of life
to be very low.
Insufficient data were available to compare secondary outcomes by
subgroups according to stimulated muscle groups or programme
duration.
D I S C U S S I O N
This review is an update of a previously published review in The
Cochrane Database of Systematic Reviews Issue 1, 2013 on Neu-
romuscular electrical stimulation for muscle weakness in adults
with advanced disease.
Summary of main results
A programme of neuromuscular electrical stimulation (NMES)
offered to people with advanced disease appears to be safe and ac-
ceptable to people with advanced disease affected by muscle weak-
ness. Compared to control conditions, NMES led to a statisti-
cally significant improvement in quadriceps muscle strength with
a moderate effect size (SMD 0.53, 95% CI 0.19 to 0.87) which,
based on the mean of standard deviations at baseline, equates to a
difference of approximately 1.1 kg. The direction and consistency
of effect was similar across subgroups with and without COPD,
and did not change when studies with a high risk of performance
or detection bias were removed from the pooled analysis. The clin-
ical relevance of this change is uncertain as a minimally impor-
tant difference for quadriceps strength has yet to be determined.
However, in people with a high level of functional impairment,
even modest changes in lower limb strength may be important
to preserve independence and prevent disability relating to daily
tasks, for example sit-to-stand transfers (Canavan 2015). Coupled
with this improvement in strength following NMES, this updated
review identified increased lower limb muscle mass. The identifi-
cation of an effect on mass appeared to be moderated by the as-
sessment modality used; it was detected within studies using more
precise measures, for example computed tomography, but not ob-
served in studies using skin-fold techniques, where measurement
error is relatively high, or whole-body assessments, which can be
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unresponsive to change. There may be instances where improve-
ments in strength represent neural changes in muscle, for exam-
ple better synchronisation of motor units during contractions, but
changes in muscle strength and mass would be expected to occur
in parallel.
Changes in secondary outcomes, including exercise performance,
were less consistent across studies. The pooled mean differences
for the ISWT and ESWT did not support an overall effect from
NMES, and the pooledmeandifference of 35m (95%CI14 to56)
for the 6MWTonlymarginally exceeded theminimally important
difference of 30 m (Holland 2014). The secondary effect of mus-
cle strengthening on exercise performance likely reflects muscle
performance as one of many limiting factors to exercise. There was
limited high-quality, randomised controlled evidence to support
effects on other outcomes. A small number of programmes led to
favourable changes in aspects of quality of life, mostly concerned
with exertional breathlessness and physical functioning. We could
not determine the most beneficial type of NMES programme due
to the diverse range of measurement tools, limited numbers of
study participants, and the degree of clinical heterogeneity among
studies.
Overall completeness and applicability of
evidence
Our findings are based on 18 studies involving 933 participants,
most of which were conducted in a single centre in a small group
of participants (fewer than 50 per study arm in 16 studies, Figure
6). Small-study bias must be considered when interpreting the
data, as the largest study by some margin shows the smallest effect
size estimate for NMES (Greening 2014). The level of supervi-
sion offered in this study was minimal, and self reported adher-
ence was low, therefore treatment infidelity might explain the dis-
crepancy in findings between this and other studies. The starting
of NMES at the onset of an acute exacerbation of disease might
also be important, though it is not possible to determine which
factor(s) contributed to the difference in findings. Other method-
ological quality markers varied across the studies we considered
in this review. The randomisation and concealment process was
generally adequately described. The majority of studies had an
apparent risk of bias arising from a lack of participant or assessor
blinding (Figure 6). Producing legitimate placebo controls for this
type of intervention can be challenging, and the lack of control-
ling for incidental features of NMES programmes might have led
to an overestimation of effect size (Maddocks 2016b). Whilst our
sensitivity analyses showed this did not affect quadriceps strength
outcomes, it may have contributed to an overestimation of effect
size for our secondary outcome measures, which could also be
influenced by performance bias and external encouragement or
feedback. Reporting bias was not apparent within the included
studies, but the degree to which selective reporting of secondary
outcomes occurred is uncertain in the absence of published pro-
tocols. Studies frequently provided sufficient information on the
setting and participants, however additional information on those
patients who refused to take part would assist in interpreting the
generalisability of findings.
Quality of the evidence
We ranked the quality of the evidence from moderate to very low
across the different outcomes. The main limiting factor, which
was the reason for downgrading quality in some outcomes, was
the inconsistency of results across studies and imprecision regard-
ing estimates of effect, especially on our secondary outcomes. We
downgraded the quality of the evidence due to the risk of bias in
studies where participants or outcome assessors, or both were not
blinded to group allocation. Overall we judged the evidence to be
of low quality, which means that further research is very likely to
have an important impact on our confidence in the estimate of
effect and is likely to change the estimate.
Potential biases in the review process
The search strategy used in this review led to the identification of
studies both in languages other than English, Sumin 2009a, and
from beyond the electronic search. The possibility remains that
additional studies have been conducted but not published. How-
ever, we are confident that the large majority of published studies
relevant to the review objectives have been identified.We collected
and analysed study data according to a predetermined protocol,
and most requests for additional information from study authors
were fulfilled, allowing formore inclusivemeta-analyses. Nonethe-
less, not all studies could be pooled due to variation in outcome,
and an acceptable but important degree of statistical heterogene-
ity was apparent within many of the meta-analyses, for example
quadriceps muscle strength (P < 0.001, I2 = 72%). We deemed
the pooling of clinical outcome data across different patient pop-
ulations to be acceptable given the similarities in the aetiology,
consequences, and reversibility of muscle dysfunction. Nonethe-
less, the classification systems used to determine advanced disease
varied across the conditions studied and were based on different
constructs, for example symptom, in NYHA 1994, versus disease-
based criteria (GOLD 2005). A performance-based measure that
can be applied across diseases would have been preferable, for ex-
ample muscle weakness, but these were rarely used as study eligi-
bility criteria, and thus could not function as an inclusion criterion
for this systematic review.
We decided to pool studies that compared NMES interventions
to usual care/no treatment, placebo, and active comparators, in-
cluding one study that compared NMES to resistance training
alongside inpatient rehabilitation (Sillen 2014a). The heterogene-
ity of comparators is acknowledged, and the effect size estimate
for NMES was lower when this study was included in our pri-
18Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
mary meta-analysis (SMD increased from 0.53 to 0.68), though
clinical heterogeneity remained high. We will consider seperate
meta-analyses according to the control addition in future review
updates. Finally, the wide range of measures limited the analysis of
secondary outcomes, and so these findings should be interpreted
cautiously.
Agreements and disagreements with other
studies or reviews
Our findings are consistent with two of three previous reviews into
the use NMES in people with cardiorespiratory disease. Roig 2009
examined five RCTs across people with COPD of any severity
and found pooled mean differences (from three studies) in peak
quadriceps torque and exercise performance of 9.6 Nm (95% CI
1.2 to 18.1) and 48 m (95% CI 9 to 86), respectively. The authors
suggested that the most impaired participants responded more
favourably to NMES, which may explain our finding of a greater
strengthening effect. Data were insufficient to draw conclusions
regarding an effect on muscle mass. Sillen 2009 described a total
of 14 studies (9 chronic heart failure; 5 COPD), again not limited
by disease severity, and concluded that NMES looked “promis-
ing as a means of rehabilitating patients”, with most studies re-
porting positive effects on skeletal muscle function, exercise ca-
pacity, and disease-specific health status. In contrast, the authors
of a recent meta-analysis in people with COPD concluded that
evidence was inadequate to support the use of NMES (Pan 2014).
Their pooled analyses did not support an effect from NMES on
quadriceps strength (4 studies; SMD 0.38, 95% CI -0.13 to 0.89)
or 6MWT distance (2 studies; MD 14m, 95% CI -17 to 45).
However, the meta-analyses excluded studies for which published
data were available (e.g. Abdellaoui 2011), which accounts for the
discrepancy in the overall finding. This underscores the need for
a comprehensive search strategy, which should include contacting
corresponding authors for primary data.
NMES has not been directly compared to alternative forms of ex-
ercise in people with advanced disease. However, comparing ev-
idence from reviews concerning participants with any severity of
disease suggests that compared toNMES, more active forms of ex-
ercise have the potential to provide equal or greater improvements
in outcome. For example, a Cochrane review of pulmonary re-
habilitation following an acute exacerbation of COPD identified
mean differences in 6MWT and ISWT distance of 78 m (95%
CI 12 to 143) and 64 m (95% CI 41 to 87), respectively (Puhan
2011), and a review of progressive resistance training in people
with COPD found weighted mean differences in quadriceps mus-
cle strength of 0.52 (95% CI 0.30 to 0.74) (O’Shea 2009). Unlike
NMES, these forms of exercise also have supporting evidence for
beneficial effect on quality of life.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The overall conclusions have not changed from the last publication
of this review, although we included more data, new analyses, and
an assessment of the quality of the evidence using the GRADE
approach in this update.
For people with advanced disease
This review suggests that NMES may be an effective treatment
for muscle weakness that can occur as a result of diseases such as
cancer, COPD, and chronic heart failure. There were no serious
safety concerns following use of NMES in a research study, though
1 in every 20 people that used NMES reported muscle soreness
following the initial few sessions. We suggest that NMES could
be used within rehabilitation programmes, though clinicians pro-
viding care may be in a position to advise further. As most studies
we considered compared NMES to a group that received no treat-
ment or a sham treatment, it is not possible to judge how NMES
compares to other forms of exercise such as weight training. There
was also very limited evidence on the effect NMES has on a per-
son’s ability to exercise or their quality of life.
For clinicians
There was low-quality evidence supporting NMES as an effec-
tive treatment for muscle weakness in adults with progressive dis-
eases such as cancer, COPD, and chronic heart failure. The studies
in our review reported no serious adverse events and a low inci-
dence of muscle discomfort. Based on this evidence, NMES could
be considered as a component treatment for use within a wider
approach to reduce disability. It is difficult to draw conclusions
about the clinical significance of the effect on muscle strength,
as a minimum clinically important difference for muscle strength
is not known, but the magnitude of the treatment effect appears
to be small to moderate and approximately a 1.1 kg change. The
evidence for an effect from NMES on exercise performance and
quality of life was of very low quality. For these outcomes, cur-
rent evidence would support the use conventional exercise training
over NMES. However, when patients are unwilling or unable to
undertake other forms of training, the evidence supports NMES
as a means to manage muscle weakness.
For policymakers
There was low-quality evidence for a strengthening effect from
NMES to manage muscle weakness in adults with advanced dis-
ease. Based on current evidence, NMES appears to lead to a short-
term, small-to-moderate increase in muscle strength as compared
to control, with a mean difference of approximately 1.1 kg. It is
difficult to draw conclusions about the clinical significance of this
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effect, as a minimum clinically important difference for muscle
strength is not known. There was very low-quality evidence for an
effect from NMES on muscle mass, exercise performance, breath-
lessness, or health-related quality of life.
For funders
There was low-quality evidence for a strengthening effect from
NMES to manage muscle weakness in adults with advanced dis-
ease, but very low quality evidence for any additional effect on
muscle mass, exercise performance, breathlessness, or health-re-
lated quality of life. Based on this evidence, NMES could be con-
sidered as a component treatment for use within a wider approach
to reduce disability, however there is very limited research onwhich
to guide this practice. Future studies should move beyond testing
whether NMES can produce a strengthening effect, and seek to
understand its role in relation to existing rehabilitation approaches.
Given the small sample sizes of current studies, larger trials may
assist in providing more robust evidence.
Implications for research
General implications
Based on current evidence, future studies should move beyond
testing whether NMES can produce a strengthening effect, and
seek to understand the role of NMES in relation to existing reha-
bilitation approaches. Studies might consider using NMES as an
adjuvant to exercise programmes to enhance their impact on mus-
cle performance, adding behaviour change components to NMES
to use gains in muscle strength to change physical activity and
dependence, or using NMES as a bridge to support patients who
demonstrate difficulty engaging in comprehensive rehabilitation
programmes.
Design
Due to the predominance of small studies, we encourage large
and pragmatic randomised controlled trials, focusing on outcomes
such as exercise performance and physical independence and/or
disability. With examples of successful placebo comparators, fu-
ture studies can avoid a ’no treatment’ arm and seek to include
a comparator that accounts for the interaction and expectation
effects of a NMES intervention. The lack of longitudinal data
should also be addressed through longer follow-up periods and/or
use of longitudinal outcomes, for example event rates or incident
disability.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Abdellaoui 2011
Methods 2-arm parallel RCT (n = 17)
Participants Inclusion criteria: acute exacerbation of COPD, age < 75 years, body mass index < 30
kg/m2
Exclusion criteria: locomotor or neurological condition or disability that could limit
ability to exercise, implanted cardiac pacemaker
Gender: 13 male, 2 female (2 unknown due to attrition)
Age: median (IQR) 59 (57, 69) and 67 (59, 72) years
Illness severity: median (IQR) FEV1 15 (10, 27) and 25 (17, 41) % predicted
Interventions NMES: bilateral quadriceps and hamstrings stimulation (35Hz, 400 µs, duty cycle 33%)
for 1 hour, 5 times each week for 6 weeks. Amplitude set to elicit visible contraction to
maximum tolerated intensity
Control: parameters as per NMES arm, amplitude set to avoid visible or palpable muscle
contraction
Outcomes Isometric quadriceps strength (hand-held dynamometry), submaximal exercise capacity
(6MWT)
Notes Standard deviations for laboratory outcomes derived from standard errors reported in
original report and from authors by request
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation
Allocation concealment (selection bias) Low risk Sealed, opaque envelopes prepared independently
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo/sham model used.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Assessors not blinded to group allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk All appropriate participants included in analysis, all at-
trition accounted for, similar across groups (1 participant
each), and not related to study intervention (disease-re-
lated readmission and family refusal)
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Abdellaoui 2011 (Continued)
Selective reporting (reporting bias) Low risk Full results provided in online supplement
Study sizes High risk < 50 participants
Akar 2015
Methods 3-arm parallel RCT (n = 30)
Participants Inclusion criteria: intubated COPD patients, GOLD stage C or D, concious, without
deep vein thrombosis (examinedwith bilateral lower extremityDoppler ultrasonography)
Exclusion criteria: patients monitored on mechanical ventilation for less than 24 h and
discharged from intensive care unit within 48 h, concurrent comorbidities (e.g. renal
failure, congestive heart failure, cerebrovascular diseases, neuromuscular diseases, diabetes
mellitus, malignancy), haemodynamically unstable patients
Gender: 15 male, 15 female
Age: mean (SD) 67 (12) years
Illness severity: GOLD stage C or D
Interventions NMES: bilateral quadriceps and deltoid muscle stimulation (50 Hz, pulse width and
duty cycle not reported) for 4 weeks, 5 times per week. NMES intensity was adjusted to
individual toleration
NMES plus active mobilisation: bilateral quadriceps and deltoid muscle stimulation as
above, plus active mobilisation using joint range of motion exercises for the upper and
lower limbs. Passive or active-assisted exercises used in participant unable to perform
active exercises
Control: active mobilisation using joint range of motion exercises for the upper and
lower limbs. Passive or active-assisted exercises used in participant unable to perform
active exercises
Outcomes Lower and upper extremitymuscle strength (manualmuscle testing), days to demonstrate
abilty to sit up in bed, at the bedside, get into standing, and transfer from bed to chair,
and intensive care unit stay in days
Notes Lower extremity muscle strength outcomes were not clearly limited to quadriceps and
were excluded from meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised”, but no further details reported.
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No placebo/sham model used.
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Akar 2015 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors blinded to group allocation.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in analysis.
Selective reporting (reporting bias) Low risk Full results provided.
Study sizes High risk < 50 participants per study arm
Bourjeily-Habr 2002
Methods 2-arm parallel RCT (n = 18)
Participants Inclusion criteria: moderate to severe COPD FEV1< 65% predicted, age < 70 years,
limited exercise tolerance
Exclusion criteria: cardiovascular or neurological condition, active or debilitating joint
disease, pulmonary rehabilitation previous 2 years
Gender: 10 male, 8 female
Age: mean (SD) 59 (2) and 62 (2) years
Illness severity: GOLD stage III/IV
Interventions NMES: bilateral quadriceps, hamstrings, and calve stimulation (50 Hz, 200 µs, duty
cycle 13%) for 1 hour (20 min each muscle), 3 times each week for 6 weeks. Amplitude
set to maximum tolerated intensity
Control: set up as per NMES arm but no active stimulation
Outcomes Isokinetic quadriceps and hamstring strength (dynamometry), maximal exercise capacity
(incremental shuttle walk test)
Notes Standard deviation derived from standard errors reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Placebo/sham model used but with no output.
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Bourjeily-Habr 2002 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors blinded to group allocation.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in analysis.
Selective reporting (reporting bias) Low risk Full results provided.
Study sizes High risk < 50 participants per study arm
Dal Corso 2007
Methods 2-arm cross-over RCT (n = 17)
Participants Inclusion criteria: COPD FEV1:FVC < 70%, MRC breathlessness score II/III, stable
medication previous 3 months
Exclusion criteria: locomotor or neurological condition, malignancy, severe endocrine,
hepatic, or renal disease, cardiac failure, implanted cardiac pacemaker, distal arteriopathy,
recent surgery, use of anticoagulant medication
Gender: 16 male, 1 female
Age: mean (SD) 66 (9) years
Illness severity: GOLD stage III/IV
Interventions NMES: bilateral quadriceps stimulation (50 Hz, 400 µs, duty cycle 16% to 33%) for
1 hour, 5 times each week for 6 weeks. Amplitude set to elicit visible contraction to
maximum tolerated intensity
Control: bilateral quadriceps stimulation (10 Hz, 50 µs, duty cycle 16% to 33%) for 1
hour, 5 times each week for 6 weeks. Amplitude limited to 10 mA set to avoid muscle
contraction
Outcomes Isokinetic quadriceps strength (dynamometry), submaximal exercise capacity (6MWT)
, body composition (DEXA)
Notes Participants included in Nápolis 2011 clinical outcomes (excluded from meta-analysis
to avoid multiplicity). Laboratory outcomes included separately. The wash-out period
was deemed sufficient to include both study phases in the meta-analysis. Results from
paired analyses were used as recommended by Elbourne 2002.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly allocated
Allocation concealment (selection bias) Unclear risk Not reported
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Dal Corso 2007 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo/sham model used.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Muscle biopsies only taken in NMES arm.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in analysis.
Selective reporting (reporting bias) Low risk Full results provided.
Study sizes High risk < 50 participants per study arm
Greening 2014
Methods 2-arm parallel RCT (n = 389)
Participants Inclusion criteria: admitted to hospital with an exacerbation of chronic respiratory dis-
ease, diagnosis of chronic respiratory disease (COPD, asthma, bronchiectasis, or ILD),
self reported breathlessness on exertion (MRC grade 3 or worse), and age ≥ 40 years
Exclusion criteria: inability to provide consent, concomitant acute cardiac event, muscu-
loskeletal, neurological, or psychiatric comorbidities, more than 4 emergency admissions
for any cause in the previous 12 months
Gender: 173 male, 216 female
Age: mean (SD) 71.1 (9.7) years
Illness severity: mean (SD) FEV1 54.7 (24.5) (82% of participants had COPD)
Interventions Early rehabilitation: bilateral NMES of the quadriceps (50 Hz, 300 ms, 15 s on and
5 s off ) for 30 minutes daily for 6 weeks. The intensity was increased by therapist or
participant in accordance with tolerance. NMES used in addition to strength and aerobic
training
Usual care: no intervention other than usual care from the ward
Outcomes Isometric quadriceps strength (dynamometer), maximal exercise capacity (ISWT), sub-
maximal exercise capacity (ESWT), health-related quality of life (SGRQ)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised on a 1:1 basis
Allocation concealment (selection bias) Low risk Automated
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Greening 2014 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding of participants was not possible. No placebo/
sham model used
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All investigators performing outcomemeasures blinded
to treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis
Selective reporting (reporting bias) Low risk Full results provided.
Study sizes Unclear risk 50 to 200 participants per study arm
Maddocks 2009a
Methods 2-arm parallel RCT (n = 16)
Participants Inclusion criteria: non-small cell lung cancer, Eastern Cooperative Oncology Group
performance status 0 to 1, < 10% weight loss
Exclusion criteria: chemotherapy or radiotherapy previous 4weeks, change inmedication
previous week, ischaemic heart disease, implanted cardiac pacemaker
Gender: 9 male, 7 female
Age: mean (SD) 64 (5) and 56 (9) years
Illness severity: locally advanced or metastatic, stage III/IV
Interventions NMES: bilateral quadriceps stimulation (50 Hz, 350 µs, duty cycle 11% to 25%) for
30 minutes daily for 4 weeks. Amplitude set to elicit visible contraction to maximum
tolerated intensity
Control: no intervention
Outcomes Isokinetic quadriceps strength (dynamometry), submaximal exercise capacity (endurance
shuttle walk test), physical activity level (accelerometer)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Permuted block generated independently.
Allocation concealment (selection bias) Low risk Using sealed, opaque envelopes
33Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Maddocks 2009a (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No placebo/sham model
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Assessors not blinded to group allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in analysis. Data on 1 par-
ticipant (NMES group) missing for each quadriceps
strength and physical activity level due to technical prob-
lems
Selective reporting (reporting bias) Low risk Full results provided.
Study sizes High risk < 50 participants per study arm
Maddocks 2013
Methods 2-arm parallel RCT (n = 49)
Participants Inclusion criteria: adults with advanced (stage IV) NSCLC confirmed by histology or
cytology, Eastern Cooperative Oncology Group performance status 0 to 2 scheduled to
receive first-line palliative chemotherapy
Exclusion criteria: spinal cord compression, epilepsy, cardiac pacemaker
Gender: 28 male, 21 female
Age: mean (SD) 69.1 (9.4) years
Illness severity: advanced stage IV NSCLC
Interventions NMES: bilateral quadriceps stimulation (50 Hz, 350 µs, duty cycle 11% to 25%)
for 30 minutes daily, at a minimum of 3 times per week, commencing 1 week after
chemotherapy started and continued for 8 or 11 weeks. Amplitude was set to elicit visible
contraction to maximum tolerated intensity
Control: no intervention
Outcomes Isometric quadriceps strength (dynamometry), body composition (DEXA), physical ac-
tivity level (accelerometer), fatigue (Multidimensional Fatigue Inventory), quality of life
(EORTC QLQ-C30)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly allocated
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Maddocks 2013 (Continued)
Allocation concealment (selection bias) Low risk Permuted block generated independently.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No placebo/sham model
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcome assessors were not blinded to the participant
group allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk All appropriate participants included in the analysis, all
attrition accounted for. Data were missing in 8 partici-
pants for body composition due to inability to scan be-
fore chemotherapy (n = 5) and participant choice (n = 3)
. 3 further participants withdrew due to NMES-related
muscle discomfort
Selective reporting (reporting bias) Low risk Full results reported.
Study sizes High risk < 50 participants per study arm
Maddocks 2016a
Methods 2-arm parallel RCT (n = 52)
Participants Inclusion criteria: aged 18 years or older, diagnosis of severe COPD consistent with
GOLD criteria (FEV1% predicted ≤ 50) and incapacitating breathlessness (MRC dys-
pnoea scale 4 or 5)
Exclusion criteria: implanted cardiac pacemaker, coexisting neurological condition, had
changes to their medication, or had experienced an acute exacerbation requiring hospi-
talisation or systemic corticosteroids in the preceding 4 weeks, regular exercisers (defined
as those enrolled in pulmonary rehabilitation or undertaking structured exercise training
≥ 3 times per week within the past month)
Interventions NMES: bilateral quadriceps stimulation (50 Hz, 350 µs, duty cycle 13% to 66%) for
30 minutes daily. Amplitude was set to elicit visible contraction to maximum tolerated
intensity
Placebo: parameters as per NMES arm, however amplitude was set between 0 mA and
20 mA to provide a sensory stimulus that was detectable by the participant
Outcomes Submaximal exercise capacity (6MWT), voluntary and involuntary isometric quadriceps
strength (dynamometer), body composition (BIA), health-related quality of life (SGRQ,
CRQ, and EQ-5D), physical activity level (accelerometer)
Notes
Risk of bias
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Maddocks 2016a (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned (1:1) at the individual level
Allocation concealment (selection bias) Low risk Randomised using an independent, web-based randomi-
sation system
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo/sham model used.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors blinded to the participant group al-
location
Incomplete outcome data (attrition bias)
All outcomes
Low risk All attrition accounted for. Data analysed by intention
to treat, and missing data were handled by a multiple
imputation approach
Selective reporting (reporting bias) Low risk Full results provided.
Study sizes High risk < 50 participants per study arm
Neder 2002
Methods 2-arm parallel RCT (n = 15)
Participants Inclusion criteria: severe COPD FEV1 < 50% predicted, MRC breathlessness score IV/
V
Exclusion criteria: locomotor or neurological condition, change in medication or exac-
erbation in previous 4 weeks
Gender: 9 male, 6 female
Age: mean (SD) 67 (8) and 65 (5) years
Illness severity: GOLD stage IV
Interventions NMES: bilateral quadriceps stimulation (50 Hz, 300 µs to 400 µs, duty cycle 11% to
25%) for 30 minutes, 5 times each week for 6 weeks. Amplitude set to elicit visible
contraction to maximum tolerated intensity
Control: no intervention
Outcomes Isokinetic and isometric quadriceps strength (dynamometry), quadriceps endurance
(constant load),maximal exercise capacity (CPET cycle ergometry), quality of life (CRQ)
Notes Control participants received NMES after the first study period, and pre-post changes
reported. These data were not used in meta-analysis. Change score for the meta-analysis
for quadriceps strength and exercise capacity were estimated using the difference between
pre- and post-intervention groups means the widest standard deviations as per a previous
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Neder 2002 (Continued)
review (Roig 2009).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised
Allocation concealment (selection bias) Low risk “Referers” blinded to sequence allocation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No placebo/sham model used.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in analysis
Selective reporting (reporting bias) Low risk Full results provided.
Study sizes High risk < 50 participants per study arm
Nuhr 2004
Methods 2-arm parallel RCT (n = 34)
Participants Inclusion criteria: symptomatic left ventricular fraction < 35%, optimised medication
Exclusion criteria: acute heart failure, angina, arrhythmia, implanted cardiac pacemaker
Gender: 29 male, 5 female
Age: mean (SD) 53 (10) years
Illness severity: NYHA stage II to IV
Interventions NMES: bilateral quadriceps and hamstrings stimulation (15Hz, 500 µs, duty cycle 33%)
for 4 hours, daily for 10 weeks. Amplitude set to elicit visible contraction to maximum
tolerated intensity
Control: parameters as per NMES arm, amplitude set to avoid visible or palpable muscle
contraction
Outcomes Maximal exercise capacity (CPET cycle ergometry), submaximal exercise capacity
(6MWT), quality of life (Minnesota Living With Heart Failure Questionnaire)
Notes
Risk of bias
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Nuhr 2004 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation list
Allocation concealment (selection bias) Low risk Sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo/sham model used.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk All attrition accounted for, small number of participants
(n = 2) and not related to study intervention (urgent
heart transplantation)
Selective reporting (reporting bias) High risk Under adverse events subheading “maximum voluntary
strength of the stimulated muscle groups did not differ
from baseline data”
Study sizes High risk < 50 participants per study arm
Nápolis 2011
Methods 2-arm cross-over RCT (n = 30)
Participants Inclusion criteria: COPD FEV1:FVC < 70%, MRC breathlessness score I/III
Exclusion criteria: locomotor or neurological condition, malignancy, severe endocrine,
hepatic, or renal disease, cardiac failure, implanted cardiac pacemaker, distal arteriopathy,
recent surgery, use of anticoagulant medication, change in medication or exacerbation
in previous 4 weeks, regular physical activity, previous pulmonary rehabilitation
Gender: 26 male, 4 female
Age: mean (SD) 64 (7) years
Illness severity: GOLD stage II/III
Interventions NMES: bilateral quadriceps stimulation (50 Hz, 300 µs to 400 µs, duty cycle 16% to
33%) for up to 1 hour, 5 times each week for 6 weeks. Amplitude set to elicit visible
contraction to maximum tolerated intensity
Control: bilateral quadriceps stimulation (50 Hz, 200 µs, duty cycle 16%) for 15 min-
utes, 3 times each week for 6 weeks. Amplitude limited to 10 mA set to avoid muscle
contraction
Outcomes Isokinetic quadriceps strength (dynamometry), maximal exercise capacity (CPET cycle
ergometry), submaximal exercise capacity (6MWT)
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Nápolis 2011 (Continued)
Notes Participants from Dal Corso 2007 were included in this study (for clinical outcomes
Nápolis 2011 datawere used inmeta-analysis to avoidmultiplicity). Thewash-out period
was deemed sufficient to include both study phases in the meta-analysis. Results from
paired analyses were used as recommended by Elbourne 2002.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk After randomisation
Allocation concealment (selection bias) Unclear risk As per Dal Corso 2007
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo/sham model used.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors blinded to participant treatment sequence
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in analysis. Data on 2 and
4 participants were missing for maximal and submax-
imal exercise capacity, respectively due to technical
problems (group allocation unknown)
Selective reporting (reporting bias) Low risk Full results provided.
Study sizes High risk < 50 participants per study arm
Quittan 2001
Methods 2-arm parallel RCT (n = 42)
Participants Inclusion criteria: severe chronic heart failure, optimised drug therapy
Exclusion criteria: unstable disease, peripheral oedema, implanted cardiac pacemaker
Gender: 21 male, 12 female
Age: mean (SD) 59 (6) and 57 (8) years
Illness severity: NYHA stage II to IV
Interventions NMES: bilateral quadriceps and hamstrings stimulation (50Hz, 700 µs, duty cycle 25%)
for up to 1 hour, 5 times each week for 8 weeks. Amplitude set to elicit visible contraction
to maximum tolerated intensity
Control: encouraged to continue engagement in usual activities of daily living recorded
in diary
39Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Quittan 2001 (Continued)
Outcomes Isokinetic and isometric quadriceps and hamstrings strength (dynamometry), quadriceps
endurance (interval fixed load), body composition (computed tomography), lower limb
functional activities (stair climb, rise from chair, rise from supine), quality of life (SF-
36)
Notes Standard deviations for outcomes of quadriceps and hamstrings strength, quadriceps
endurance, and body composition were derived from reported 95% confidence intervals
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block-wise randomisation using list provided by inde-
pendent staff
Allocation concealment (selection bias) Low risk Randomisation code locked until the end of the study
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No placebo/sham model
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were not aware of the participants’ group allo-
cation
Incomplete outcome data (attrition bias)
All outcomes
Low risk All attrition accounted for, similar numbers across
groups (NMES n = 2, control n = 5) and not related
to study intervention (urgent heart transplantation n =
6, pacemaker implanted n = 1, renal failure n = 1, died
(control) n = 1)
Selective reporting (reporting bias) Low risk Full results provided.
Study sizes High risk < 50 participants per study arm
Sillen 2014a
Methods 3-arm parallel RCT (n = 120)
Participants Inclusion criteria: primary diagnosis of COPD, baseline MRC dyspnoea grade 3 or 4,
quadriceps weakness (peak torque ≤ 80% predicted)
Exclusion criteria: neuromuscular diseases, joint disorders in hip/leg and/or knees, metal
implants in hip, leg, and/or knee, cardiac pacemaker or internal cardiac defibrillator,
and/or outpatient pulmonary rehabilitation programme
Gender: 62 male, 58 female
Age: mean (SD) 64.8 (8.8) years
Illness severity: mean (SD) FEV1 33 (11) % predicted
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Sillen 2014a (Continued)
Interventions High-frequency NMES: bilateral quadriceps and calf muscle stimulation (75 Hz, 400
µs, duty cycle was 38%) for 8 weeks, twice per day, 5 times per week. After a 3-minute
warm-up at 5 Hz, intensity was adjusted to individual toleration during each 18-minute
session
Low-frequency NMES: same as the high-frequency NMES protocol, however the fre-
quency used was 15 Hz
Control: strength training consisting of bilateral leg extension and bilateral leg press
exercises at 70% 1 RPM, 4 sets of 8 for each exercise with at least 2 minutes of recovery
between sets. Training load was set to increase by 5% every 2 weeks
Outcomes Isokinetic quadriceps muscle strength (dynamometry), isokinetic quadriceps endurance
(constant load), submaximal exercise capacity (6MWT), endurance (constant work rate
cycle endurance test), anxiety and depression (HADS), health-related quality of life
(SGRQ), problematic activities of daily living (COPM)
Notes Standard deviations for laboratory outcomes derived from standard errors reported in
the original paper
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation schedule generated by a computer.
Allocation concealment (selection bias) Low risk Sequence was concealed.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants randomly assigned to one of the NMES
groups were blinded for stimulation frequency, how-
ever no placebo/sham in the control group (the main
comparison for this review)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Randomisation schedule was maintained centrally, and
the investigator was not involved in the assessment and
treatment of participants. Investigators supervising the
interventions were blinded for initial results, and were
not involved in the initial or outcome assessments
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No imputations. Attrition accounted for but not sim-
ilar between the groups, highest attrition in the low-
frequency group
Selective reporting (reporting bias) Low risk Full results provided.
Study sizes High risk < 50 participants per study arm
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Tasdemir 2015
Methods 2-arm parallel RCT (n = 34)
Participants Inclusion criteria: aged between 40 and 75 years, eligible to participate in exercise, no
acute exacerbations within the past month, and no drug or antibiotic usage within the
past 4 weeks
Exclusion criteria: suffering from orthopaedic or neuromuscular disorders, metal im-
plants in the lower limb, suffered from advanced heart failure, aortic stenosis, or deep
vein thrombosis, required cardiac pacemaker, had a pulmonary artery pressure > 50
mmHg, suffered an acute exacerbation within the past 4 weeks, unable to understand
the questionnaires, and were unable to co-operate
Gender: 24 male, 3 female
Age: mean (SD) 62.1 (7.9) and 62.9 (7.5) years
Illness severity: GOLD stages 1 = 0, II = 9, III = 9, IV = 9
Interventions NMES: bilateral quadriceps stimulation (50 Hz, 300 µs, duty cycle was 50%) for 20
minutes, 2 days per week, for 10 weeks. Intensity was increased to each participant’s
maximum individual tolerance level
Control: parameters as per NMES arm, with the exception of stimulation frequency of
5 Hz, which caused a visible twitch
All participants undertook a pulmonary rehabilitation programme consisting of exercise
training and additional intervention such as education and nutritional and psycholog-
ical support. Exercise training consisted of 10 weeks of endurance training, quadriceps
resistance training, and low-level resistance training for the upper limbs
Outcomes Maximal exercise capacity (ISWT), submaximal exercise capacity (ESWT), body com-
position (BIA), quadriceps function (1-repetition maximum and 30-second sit-to-stand
test), quadriceps endurance (squat test and 2-minute step-in-place test), health-related
quality of life (SGRQ)
Notes Mean and standard deviation values were estimated from reported median and range
values using the formulae published by Hozo 2005.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation list
Allocation concealment (selection bias) Low risk Sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo/sham model used.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Assessors were not blinded for the final evaluation assess-
ment
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Tasdemir 2015 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All attrition accounted for, similar across groups (NMES
n=4, control n = 3) and not related to study intervention
Selective reporting (reporting bias) Low risk Full results provided.
Study sizes High risk < 50 participants per study arm
Vieira 2014
Methods 2-arm parallel RCT (n = 30)
Participants Inclusion criteria: diagnosis of COPD with FEV1 < 50% predicted, self reported dysp-
noea and/or arm fatigue during at least 1 activity of daily living that required arm exercise
Exclusion criteria: musculoskeletal or neurological condition that could affect exercise
performance, symptomatic cardiac disease or previous lung surgery, an acute exacerbation
of COPD that required a change in pharmacological management within the preceding
2 months, use of oral corticosteroids, a change in medication dosage or exacerbation of
symptoms in the preceding 12 weeks, implantable electrical devices
Gender: 24 male, 0 female
Age: mean (SD) 56.4 (11.8) years
Illness severity: GOLD stage III/IV, mean (SD) 38.1 (12.4)% predicted
Interventions NMES: bilateral quadriceps stimulation (50 Hz, 300 µs to 400 µs, duty cycle 10% to
33%) for 60 minutes per session, 5 times per week, twice per day for 8 weeks. Amplitude
was set to elicit visible contraction to maximum tolerated intensity
Control: parameters as per NMES arm, but no active stimulation
All participants received respiratory physiotherapy, i.e. breathing and stretching exercises
Outcomes Submaximal exercise capacity (6MWT), cardiopulmonary exercise testing (constant
work test at 80% peak workload), body composition (BIA), quality of life (SGRQ)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly allocated
Allocation concealment (selection bias) Low risk 2 investigators were blinded to the order of participant
allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Active and sham devices were utilised, however the sham
device produced no stimulation
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Vieira 2014 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Within group health-related quality of life reporting
Incomplete outcome data (attrition bias)
All outcomes
High risk 17%attrition, causing an imbalance between the groups.
Increased dropouts due to an exacerbation in the control
group compared to the NMES group
Selective reporting (reporting bias) Low risk Full results provided.
Study sizes High risk < 50 participants per study arm
Vivodtzev 2006
Methods 2-arm parallel RCT (n = 17)
Participants Inclusion criteria: severe COPD, COPD FEV1:FVC < 70%, FEV1 < 50% predicted,
body mass index < 22 kg/m2, quadriceps maximum voluntary strength < 50% predicted
Exclusion criteria: cardiovascular, renal, or hepatic disease, acute respiratory failure
Gender: 11 male, 6 female
Age: mean (SD) 59 (15) and 68 (12) years
Illness severity: GOLD stage IV
Interventions NMES: bilateral quadriceps stimulation (35Hz, 400 µs, duty cycle 47%) for 30minutes,
4 times each week for 4 weeks. Amplitude set to elicit visible contraction to maximum
tolerated intensity. Additional usual rehabilitation as described below
Control: usual rehabilitation limb mobilisations, slow treadmill walking, light upper
limb resistance training for ~30 minutes, 4 times each week for 4 weeks
Outcomes Isometric quadriceps strength (dynamometry), submaximal exercise capacity (6MWT)
, body composition (anthropometry), quality of life (Maugeri Foundation Respiratory
Failure Questionnaire)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised into 2 groups
Allocation concealment (selection bias) Unclear risk Inadequately described to judge
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No placebo/sham model used.
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Vivodtzev 2006 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Body composition assessments optional
Selective reporting (reporting bias) Low risk Full results provided, body composition assessments op-
tional, similar numbers across groups (NMES n = 6,
control n = 5)
Study sizes High risk < 50 participants per study arm
Vivodtzev 2012
Methods 2-arm parallel RCT (n = 22)
Participants Inclusion criteria: severe COPD FEV1:FVC < 70%, FEV1 < 50% predicted, 6-minute
walking distance < 400 metres, > 20-year smoking pack-year history, sedentary lifestyle,
< 1 hour from hospital
Exclusion criteria: acute exacerbation or systemic steroids in previous 4 weeks, condition
associated with muscle wasting including active inflammatory illness, heart failure, or
diabetes
Gender: 13 male, 7 female
Age: mean (SD) 68 (9) and 70 (3) years
Illness severity: GOLD stage IV
Interventions NMES: bilateral quadriceps and calve stimulation (50 Hz, 400 µs, duty cycle 27%) for
1 hour (35 minutes quadriceps and 25 minutes calves), 5 times each week for 6 weeks.
Amplitude set to elicit visible contraction to maximum tolerated intensity
Control: bilateral quadriceps stimulation (5 Hz, 100 µs, continuous) for 1 hour (35
minutes quadriceps and 25 minutes calves), 5 times each week for 6 weeks
Outcomes Isometric quadriceps strength (dynamometry), quadriceps endurance (constant load test)
, body composition (computed tomography), submaximal exercise capacity (endurance
shuttle walk test)
Notes Standard deviations for all outcomes derived from standard errors reported in original
report and from authors by request
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly assigned
Allocation concealment (selection bias) Unclear risk Inadequately described to judge
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Vivodtzev 2012 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo/sham model used.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Inadequately described to judge
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in analysis
Selective reporting (reporting bias) Low risk Full results provided.
Study sizes High risk < 50 participants per study arm
Zanotti 2003
Methods 2-arm parallel RCT (n = 24)
Participants Inclusion criteria: chronic hypercapnic respiratory failure, COPD FEV1:FVC < 70%,
mechanically ventilated, severe peripheral muscle atrophy, bed-bound > 30 days
Exclusion criteria: condition or disease other than COPD, change in medication within
previous 4 weeks, corticosteroid use > 5 days whilst on intensive care unit
Gender: 17 male, 7 female
Age: mean (SD) 68 (8) and 65 (4) years
Illness severity: respiratory failure due to COPD
Interventions NMES: bilateral quadriceps and glutei stimulation (35 Hz, 350 µs, duty cycle not re-
ported) for 30 minutes, 5 times each week for 4 weeks. Amplitude not reported. Used
as adjunct to active limb mobilisation described below
Control: active limb mobilisation of upper and lower limbs for up to 30 minutes within
participant tolerance, 5 times each week for 4 weeks
Outcomes Peripheral muscle strength (manual muscle testing), number of days to transfer from bed
to chair
Notes Peripheral muscle strength outcome not clearly limited to quadriceps and excluded from
meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned
Allocation concealment (selection bias) Unclear risk Inadequately described to judge
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Zanotti 2003 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No placebo/sham model used.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors blinded to group allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in analysis
Selective reporting (reporting bias) Low risk Full results provided.
Study sizes High risk < 50 participants per study arm
Abbreviations: 6MWT = 6-minute walk test, BIA = bioelectrical impedance analysis, COPD = chronic obstructive pulmonary disease,
COPM = Canadian Occupational Performance Measure, CPET = cardiopulmonary exercise testing, CRQ = Chronic Respiratory
Questionnaire, DEXA = dual energy X-ray absorptiometry, EORTC QLQ-C30 = European Organisation for the Research and
Treatment of CancerQuality of Life Core 30, ESWT= endurance shuttle walk test, FEV1 forced expiratory volume in 1 second, FVC
= forced vital capacity, HADS = Hospital Anxiety and Depression Scale, ILD = interstitial lung disease, IQR = interquartile range,
ISWT = incremental shuttle walk test, mA = maximum amplitude, MRC = Medical Research Council, NMES = neuromuscular
electrical stimulation, NSCLC = non-small cell lung cancer, NYHA = New York Heart Association, RCT = randomised controlled
trial, RPM = revolutions per minute, SD = standard deviation, SF-36 = 36-Item Short Form Health Survey, SGRQ = St George’s
Respiratory Disease Questionnaire
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ambrosino 2004 Review, perspective
Ambrosino 2008 Review, perspective
Arena 2010 Review, perspective
Banerjee 2009 The majority of participants (9/10) had early-stage (NYHA II) disease
Banerjee 2010 Review, perspective
Bausewein 2008 Review, meta-analysis
Bax 2005 Review, perspective
Bertoti 2000 Review, perspective
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(Continued)
Bustamante 2010 The intervention studied involved magnetic rather than electrical stimulation to elicit a muscular contraction
Carvalho 2011 Acute-effects study
Chaplin 2013 The study compared high-frequency and low-frequency NMES, no comparison to an inactive control or an
active control such as exercise present
Claydon 2010 Poststroke
Collier 2009 Observation
Coote 2015 Difficult to define advanced disease in multiple sclerosis
Crevenna 2003 Case series
Crevenna 2004 Case series
Crevenna 2006 Case report
Dehail 2008 Review, perspective
Deley 2005 The majority of participants (18/24) had early-stage (NYHA II) disease
Deley 2008 Observational
Dobsák 2006a The majority of participants (22/30) had early-stage (NYHA II) disease
Dobsák 2006b Observational
Dourado 2004 Review, perspective
Duffell 2008 Spinal cord injury
Ergun 2010 Group allocation reportedly occurred according to level of illness severity and muscle dysfunction: “due to
illness severity and muscle dysfunction 8 patients were included in NMES and 11 patients were included in
endurance program”
Gaines 2004 Osteoarthritis
Gerovasili 2009 Critically ill patient including sepsis and trauma
Giavedoni 2010 Randomisation occurred at the level of the limb, with one leg stimulated and the other acting as a control
Gremeaux 2008 Total hip replacement
Gruther 2010 Critically ill patient including sepsis and trauma
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(Continued)
Harris 2003 The majority of participants (35/46) had early-stage (NYHA II) disease
Hennessy 2010a Acute-effects study
Hennessy 2010b Acute-effects study
Jancik 2003 Observational
Karavidas 2010 Frequency-matched case-control
Kaymaz 2015 Observational
Larsen 2004 Review, perspective
LeMaitre 2006 The majority of participants (28/35) had early-stage (NYHA II) disease
Maddocks 2007 Review, perspective
Mador 2000 Assessment using ES not intervention
Maffiuletti 2010 Review, perspective
Maillefert 1998 Observational
Malaguti 2009 Compared 2 intensity protocols
Marsolais 1983 Spinal cord injury, paralysis
Middlekauff 2010 Review, perspective
Mifkova 2004 Observational
Needham 2009 Review, perspective
Palmieri-Smith 2010 Osteoarthritis
Piepoli 2010 Review, perspective
Piva 2007 Case series
Quittan 1999 Observational
Roig 2009 Review, meta-analysis
Routsi 2010 Critically ill patient including sepsis and trauma
Sbruzzi 2010 Review, meta-analysis
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(Continued)
Sbruzzi 2011 Compared 2 NMES frequencies
Scott 2007 Assessment using ES not intervention
Sheffler 2007 Review, perspective
Sillen 2008 Acute-effects study
Sillen 2009 Review, meta-analysis
Sillen 2010 Acute-effects study
Sillen 2011 Acute-effects study
Sillen 2014b Measurements made following 1 session/acute-effects study.
Stevens-Lapsley 2012 Total knee replacement
Strasser 2009 Abdominal surgery
Sumin 2008 Repeat report
Sumin 2009a The majority of participants (99/101) had early-stage disease
Sumin 2009b Repeat report
Talbot 2003 Osteoarthritis
Vaquero 1998 Post-cardiac transplantation
Vivodtzev 2008 Review, perspective
Vivodtzev 2009 Review, perspective
Vivodtzev 2010 Repeat report
Vivodtzev 2014 Repeat report
Walls 2010 Total knee replacement
Windholz 2011 Observational
NMES = neuromuscular electrical stimulation, NYHA = New York Heart Association
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D A T A A N D A N A L Y S E S
Comparison 1. Neuromuscular electrical stimulation versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Quadriceps muscle strength 12 781 Std. Mean Difference (IV, Random, 95% CI) 0.53 [0.19, 0.87]
2 Muscle mass 8 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Anthropometry 2 31 Std. Mean Difference (IV, Random, 95% CI) 0.69 [-0.05, 1.42]
2.2 Dual energy X-ray
absorptiometry (DEXA)
3 179 Std. Mean Difference (IV, Random, 95% CI) 0.09 [-0.20, 0.38]
2.3 Ultrasound 1 52 Std. Mean Difference (IV, Random, 95% CI) 0.82 [0.26, 1.39]
2.4 Computed tomography 2 52 Std. Mean Difference (IV, Random, 95% CI) 1.01 [0.42, 1.60]
3 Exercise performance 13 Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 6-minute walk test (m)
(6MWT)
7 317 Mean Difference (IV, Random, 95% CI) 34.78 [13.52, 56.05]
3.2 Incremental shuttle walk
test (m) (ISWT)
3 434 Mean Difference (IV, Random, 95% CI) 8.72 [-34.87, 52.31]
3.3 Endurance shuttle walk
test (m) (ESWT)
4 452 Mean Difference (IV, Random, 95% CI) 64.13 [-17.79, 146.
05]
3.4 Cardiopulmonary exercise
testing (mL/min) (CPET)
4 109 Mean Difference (IV, Random, 95% CI) 44.82 [-7.34, 96.99]
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Analysis 1.1. Comparison 1 Neuromuscular electrical stimulation versus control, Outcome 1 Quadriceps
muscle strength.
Review: Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease
Comparison: 1 Neuromuscular electrical stimulation versus control
Outcome: 1 Quadriceps muscle strength
Study or subgroup NMES Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Abdellaoui 2011 9 8.4 (4) 6 3.5 (3.2) 5.1 % 1.24 [ 0.09, 2.40 ]
Bourjeily-Habr 2002 9 10.5 (19.8) 9 3.9 (18.6) 6.4 % 0.33 [ -0.60, 1.26 ]
Greening 2014 196 1.17 (7.58) 193 0.69 (8.34) 12.1 % 0.06 [ -0.14, 0.26 ]
Maddocks 2009a 7 7.4 (10.3) 8 -2 (9) 5.5 % 0.92 [ -0.16, 2.00 ]
Maddocks 2013 13 0.6 (1.8) 12 -0.5 (1.8) 7.3 % 0.59 [ -0.21, 1.40 ]
Maddocks 2016a 25 3.4 (5.2) 27 0.3 (4.4) 9.4 % 0.64 [ 0.08, 1.19 ]
Neder 2002 9 27.4 (32.3) 8 5.2 (16.2) 6.0 % 0.81 [ -0.19, 1.81 ]
N polis 2011 30 0.2 (11.2) 30 1.6 (11.8) 9.8 % -0.12 [ -0.63, 0.39 ]
Quittan 2001 17 21.4 (15.2) 16 -8.9 (11.5) 6.8 % 2.18 [ 1.30, 3.07 ]
Sillen 2014a 33 10.8 (16.7) 29 6.1 (10.8) 9.9 % 0.33 [ -0.18, 0.83 ]
Sillen 2014a 29 1.4 (9.7) 29 6.1 (10.8) 9.7 % -0.45 [ -0.97, 0.07 ]
Vivodtzev 2006 9 97 (71) 8 36 (35) 5.8 % 1.01 [ -0.01, 2.04 ]
Vivodtzev 2012 12 11 (18.7) 8 -2.8 (5.1) 6.3 % 0.88 [ -0.06, 1.83 ]
Total (95% CI) 398 383 100.0 % 0.53 [ 0.19, 0.87 ]
Heterogeneity: Tau2 = 0.23; Chi2 = 42.80, df = 12 (P = 0.00002); I2 =72%
Test for overall effect: Z = 3.09 (P = 0.0020)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours control Favours NMES
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Analysis 1.2. Comparison 1 Neuromuscular electrical stimulation versus control, Outcome 2 Muscle mass.
Review: Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease
Comparison: 1 Neuromuscular electrical stimulation versus control
Outcome: 2 Muscle mass
Study or subgroup NMES Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Anthropometry
Vieira 2014 11 0.95 (0.58) 9 0.03 (1.94) 65.5 % 0.65 [ -0.26, 1.55 ]
Vivodtzev 2006 6 1.1 (0.9) 5 0.1 (1.5) 34.5 % 0.76 [ -0.49, 2.01 ]
Subtotal (95% CI) 17 14 100.0 % 0.69 [ -0.05, 1.42 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.83 (P = 0.068)
2 Dual energy X-ray absorptiometry (DEXA)
Dal Corso 2007 17 -0.07 (1.48) 17 0.06 (1.37) 19.1 % -0.09 [ -0.76, 0.58 ]
Maddocks 2013 13 -0.4 (0.4) 12 -0.4 (0.8) 14.0 % 0.0 [ -0.78, 0.78 ]
Sillen 2014a 29 0.44 (0.97) 29 0.37 (0.7) 32.5 % 0.08 [ -0.43, 0.60 ]
Sillen 2014a 33 0.58 (1.03) 29 0.37 (0.7) 34.4 % 0.23 [ -0.27, 0.73 ]
Subtotal (95% CI) 92 87 100.0 % 0.09 [ -0.20, 0.38 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.64, df = 3 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
3 Ultrasound
Maddocks 2016a 25 73.3 (74.5) 27 3.7 (90.5) 100.0 % 0.82 [ 0.26, 1.39 ]
Subtotal (95% CI) 25 27 100.0 % 0.82 [ 0.26, 1.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.84 (P = 0.0045)
4 Computed tomography
Quittan 2001 17 12.8 (14.4) 15 2 (9.2) 65.2 % 0.86 [ 0.13, 1.59 ]
Vivodtzev 2012 12 2.7 (2.6) 8 -0.5 (2) 34.8 % 1.29 [ 0.29, 2.28 ]
Subtotal (95% CI) 29 23 100.0 % 1.01 [ 0.42, 1.60 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.46, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 3.35 (P = 0.00081)
Test for subgroup differences: Chi2 = 11.09, df = 3 (P = 0.01), I2 =73%
-4 -2 0 2 4
Favours control Favours NMES
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Analysis 1.3. Comparison 1 Neuromuscular electrical stimulation versus control, Outcome 3 Exercise
performance.
Review: Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease
Comparison: 1 Neuromuscular electrical stimulation versus control
Outcome: 3 Exercise performance
Study or subgroup NMES Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 6-minute walk test (m) (6MWT)
Abdellaoui 2011 9 181 (94) 6 65.6 (46) 6.5 % 115.40 [ 43.80, 187.00 ]
Maddocks 2016a 25 29.9 (51) 27 -5.7 (35.7) 18.9 % 35.60 [ 11.50, 59.70 ]
Nuhr 2004 17 72 (138) 15 6 (145) 3.9 % 66.00 [ -32.43, 164.43 ]
N polis 2011 30 10.2 (28.6) 30 9.5 (37.9) 21.5 % 0.70 [ -16.29, 17.69 ]
Sillen 2014a 33 66 (80.4) 29 29 (64.6) 14.5 % 37.00 [ 0.87, 73.13 ]
Sillen 2014a 29 51 (80.8) 29 29 (64.6) 14.0 % 22.00 [ -15.65, 59.65 ]
Vieira 2014 11 75.6 (71.3) 9 0.8 (95.2) 6.1 % 74.80 [ -0.32, 149.92 ]
Vivodtzev 2006 9 63 (40) 9 30 (38) 14.5 % 33.00 [ -3.05, 69.05 ]
Subtotal (95% CI) 163 154 100.0 % 34.78 [ 13.52, 56.05 ]
Heterogeneity: Tau2 = 471.56; Chi2 = 17.48, df = 7 (P = 0.01); I2 =60%
Test for overall effect: Z = 3.21 (P = 0.0013)
2 Incremental shuttle walk test (m) (ISWT)
Bourjeily-Habr 2002 9 68.8 (65.4) 9 0 (40.5) 26.8 % 68.80 [ 18.54, 119.06 ]
Greening 2014 196 41 (106.9) 193 38 (105.6) 37.9 % 3.00 [ -18.12, 24.12 ]
Tasdemir 2015 13 38.4 (41.8) 14 69.2 (33.6) 35.3 % -30.80 [ -59.54, -2.06 ]
Subtotal (95% CI) 218 216 100.0 % 8.72 [ -34.87, 52.31 ]
Heterogeneity: Tau2 = 1187.73; Chi2 = 11.68, df = 2 (P = 0.003); I2 =83%
Test for overall effect: Z = 0.39 (P = 0.69)
3 Endurance shuttle walk test (m) (ESWT)
Greening 2014 196 108.4 (256.8) 193 71.1 (224.8) 58.3 % 37.30 [ -10.64, 85.24 ]
Maddocks 2009a 8 -20 (254) 8 -159 (222) 10.5 % 139.00 [ -94.76, 372.76 ]
Tasdemir 2015 13 153 (180) 14 230 (415) 10.2 % -77.00 [ -315.39, 161.39 ]
Vivodtzev 2012 12 174 (249) 8 5 (76) 21.1 % 169.00 [ 18.60, 319.40 ]
Subtotal (95% CI) 229 223 100.0 % 64.13 [ -17.79, 146.05 ]
Heterogeneity: Tau2 = 2400.12; Chi2 = 4.32, df = 3 (P = 0.23); I2 =30%
Test for overall effect: Z = 1.53 (P = 0.12)
4 Cardiopulmonary exercise testing (mL/min) (CPET)
-200 -100 0 100 200
Favours control Favours NMES
(Continued . . . )
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(. . . Continued)
Study or subgroup NMES Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bourjeily-Habr 2002 9 52 (114) 9 -16 (76) 34.0 % 68.00 [ -21.51, 157.51 ]
Neder 2002 9 120 (160) 6 60 (190) 8.0 % 60.00 [ -124.50, 244.50 ]
N polis 2011 28 -13 (136.4) 28 -37.7 (132.3) 54.9 % 24.70 [ -45.68, 95.08 ]
Vieira 2014 11 100 (453) 9 -8 (191) 3.1 % 108.00 [ -187.36, 403.36 ]
Subtotal (95% CI) 57 52 100.0 % 44.82 [ -7.34, 96.99 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.77, df = 3 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.68 (P = 0.092)
Test for subgroup differences: Chi2 = 1.97, df = 3 (P = 0.58), I2 =0.0%
-200 -100 0 100 200
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A P P E N D I C E S
Appendix 1. Search strategies
2016 search strategies
CENTRAL, DARE & CDSR (the Cochrane Library)
#1 MeSH descriptor: [Electric Stimulation Therapy] explode all trees
#2 ((muscle* or muscular or neuromuscular or neuro-muscular) and electric* and stimulat*):ti,ab,kw (Word variations have been
searched)
#3 NMES:ti,ab,kw (Word variations have been searched)
#4 #1 or #2 or #3
#5 MeSH descriptor: [Muscle Weakness] this term only
#6 ((muscle* or muscular) and (weak* or fatigue or strength)):ti,ab,kw (Word variations have been searched)
#7 #5 or #6
#8 (advance* near/6 (disease* or illness*)):ti,ab,kw (Word variations have been searched)
#9 MeSH descriptor: [Neoplasms] explode all trees
#10 (cancer* or neoplas* ormalignan* or carcinoma* or tumor* or tumour* ormetasta* or adenocarcinoma* or lymphoma* or leukemia*
or leukaemia*):ti,ab,kw (Word variations have been searched)
#11 MeSH descriptor: [Pulmonary Disease, Chronic Obstructive] explode all trees
#12 (chronic and obstruct* and (pulmonary or airway* or airflow or lung*)):ti,ab,kw (Word variations have been searched)
#13 COPD:ti,ab,kw (Word variations have been searched)
#14 ((pulmonary or respiratory) near/6 disease*):ti,ab,kw (Word variations have been searched)
#15 MeSH descriptor: [Heart Diseases] explode all trees
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#16 (((cardi* or heart) near/6 (disease* or failure)) or CHF):ti,ab,kw (Word variations have been searched)
#17 MeSH descriptor: [HIV] explode all trees
#18 human immunodeficiency virus*:ti,ab,kw (Word variations have been searched)
#19 human immuno-deficiency virus*:ti,ab,kw (Word variations have been searched)
#20 acquired immunodeficiency syndrome*:ti,ab,kw (Word variations have been searched)
#21 acquired immuno-deficiency syndrome*:ti,ab,kw (Word variations have been searched)
#22 (HIV or AIDS):ti,ab,kw (Word variations have been searched)
#23 (#8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22)
#24 (#4 and #7 and #23)
MEDLINE (OVID)
1 exp Electric Stimulation Therapy/
2 ((muscle* or muscular or neuromuscular or neuro-muscular) and electric* and stimulat*).mp.
3 NMES.mp.
4 or/1-3
5 Muscle Weakness/
6 ((muscle* or muscular) and (weak* or fatigue or strength)).mp.
7 5 or 6
8 (advance* adj6 (disease* or illness*)).mp.
9 exp neoplasms/
10 (cancer* or neoplas* or malignan* or carcinoma* or tumor* or tumour* or metasta* or adenocarcinoma* or lymphoma* or leukemia*
or leukaemia*).mp.
11 exp Pulmonary Disease, Chronic Obstructive/
12 (chronic and obstruct* and (pulmonary or airway* or airflow or lung*)).mp.
13 COPD.mp.
14 ((pulmonary or respiratory) adj6 disease*).mp.
15 exp heart diseases/
16 (((cardi* or heart) adj6 (disease* or failure)) or CHF).mp.
17 exp HIV/
18 human immunodeficiency virus*.mp.
19 human immuno-deficiency virus*.mp.
20 acquired immunodeficiency syndrome*.mp.
21 acquired immuno-deficiency syndrome*.mp.
22 (HIV or AIDS).mp.
23 or/8-22
24 4 and 7 and 23
25 (201207* or 201208* or 201209* or 201210* or 201211* or 201212* or 2013* or 2014* or 2015* or 2016*).ed.
26 24 and 25
Embase (OVID)
1 neuromuscular electrical stimulation/
2 ((muscle* or muscular or neuromuscular or neuro-muscular) and electric* and stimulat*).mp.
3 NMES.mp.
4 or/1-3
5 exp Muscle Weakness/
6 ((muscle* or muscular) and (weak* or fatigue or strength)).mp.
7 5 or 6
8 (advance* adj6 (disease* or illness*)).mp.
9 exp neoplasm/
10 (cancer* or neoplas* or malignan* or carcinoma* or tumor* or tumour* or metasta* or adenocarcinoma* or lymphoma* or leukemia*
or leukaemia*).mp.
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11 chronic obstructive lung disease/
12 (chronic and obstruct* and (pulmonary or airway* or airflow or lung*)).mp.
13 COPD.mp.
14 ((pulmonary or respiratory) adj6 disease*).mp.
15 exp heart disease/
16 (((cardi* or heart) adj6 (disease* or failure)) or CHF).mp.
17 exp Human immunodeficiency virus/
18 human immunodeficiency virus*.mp.
19 human immuno-deficiency virus*.mp.
20 acquired immunodeficiency syndrome*.mp.
21 acquired immuno-deficiency syndrome*.mp.
22 (HIV or AIDS).mp.
23 or/8-22
24 4 and 7 and 23
25 (201207* or 201208* or 201209* or 201210* or 201211* or 201212* or 2013* or 2014* or 2015* or 2016*).dd.
26 24 and 25
27 random$.tw.
28 factorial$.tw.
29 crossover$.tw.
30 cross over$.tw.
31 cross-over$.tw.
32 placebo$.tw.
33 (doubl$ adj blind$).tw.
34 (singl$ adj blind$).tw.
35 assign$.tw.
36 allocat$.tw.
37 volunteer$.tw.
38 Crossover Procedure/
39 double-blind procedure.tw.
40 Randomized Controlled Trial/
41 Single Blind Procedure/
42 or/27-41
43 (animal/ or nonhuman/) not human/
44 42 not 43
45 26 and 44
PsycINFO (OVID)
1 ((muscle* or muscular or neuromuscular or neuro-muscular) and electric* and stimulat*).mp.
2 NMES.mp.
3 ((muscle* or muscular) and (weak* or fatigue or strength)).mp.
4 (advance* adj6 (disease* or illness*)).mp.
5 exp neoplasm/
6 (cancer* or neoplas* or malignan* or carcinoma* or tumor* or tumour* or metasta* or adenocarcinoma* or lymphoma* or leukemia*
or leukaemia*).mp.
7 chronic obstructive pulmonary disease/
8 (chronic and obstruct* and (pulmonary or airway* or airflow or lung*)).mp.
9 COPD.mp.
10 ((pulmonary or respiratory) adj6 disease*).mp.
11 exp heart disorders/
12 (((cardi* or heart) adj6 (disease* or failure)) or CHF).mp.
13 exp Human immunodeficiency virus/
14 human immunodeficiency virus*.mp.
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15 human immuno-deficiency virus*.mp.
16 acquired immunodeficiency syndrome*.mp.
17 acquired immuno-deficiency syndrome*.mp.
18 (HIV or AIDS).mp.
19 or/4-18
20 1 or 2
21 3 and 19 and 20
22 limit 21 to yr=“2012 -Current”
CINAHL (EBSCO)
S26 S24 AND S25
S25 EM 20120701-20150131
S24 S4 AND S7 AND S23
S23 S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22
S22 (HIV or AIDS)
S21 acquired immuno-deficiency syndrome*
S20 acquired immunodeficiency syndrome*
S19 human immuno-deficiency virus*
S18 human immunodeficiency virus*
S17 (MH “Human Immunodeficiency Virus+”)
S16 (((cardi* or heart) N6 (disease* or failure)) or CHF)
S15 (MH “Heart Diseases+”)
S14 ((pulmonary or respiratory) N6 disease*)
S13 COPD
S12 (chronic and obstruct* and (pulmonary or airway* or airflow or lung*))
S11 (MH “Pulmonary Disease, Chronic Obstructive+”)
S10 (cancer* or neoplas* or malignan* or carcinoma* or tumor* or tumour* or metasta* or adenocarcinoma* or lymphoma* or
leukemia* or leukaemia*)
S9 (MH “Neoplasms+”)
S8 (advance* N6 (disease* or illness*))
S7 S5 OR S6
S6 ((muscle* or muscular) and (weak* or fatigue or strength))
S5 (MH “Muscle Weakness”)
S4 S1 OR S2 OR S3
S3 NMES
S2 ((muscle* or muscular or neuromuscular or neuro-muscular) and electric* and stimulat*)
S1 (MH “Electric Stimulation+”)
2012 search strategies
MEDLINE, CINAHL, EMBASE, and PsycINFO (Ovid Web)
1. exp Electric Stimulation Therapy/
2. ((muscle* or muscular or neuromuscular or neuro-muscular) and electric* and stimulat*).mp.
3. NMES.mp.
4. 1 or 2 or 3
5. Muscle Weakness/
6. ((muscle* or muscular) and (weak* or fatigue or strength)).mp.
7. 5 or 6
8. (advance* adj6 (disease* or illness*)).mp.
9. exp neoplasms/
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10. (cancer* or neoplas* ormalignan* or carcinoma* or tumor* or tumour* ormetasta* or adenocarcinoma* or lymphoma* or leukemia*
or leukaemia*).mp.
11. exp Pulmonary Disease, Chronic Obstructive/
12. (chronic and obstruct* and (pulmonary or airway* or airflow or lung*)).mp.
13. COPD.mp.
14. ((pulmonary or respiratory) adj6 disease*).mp.
15. exp heart diseases/
16. (((cardi* or heart) adj6 (disease* or failure)) or CHF).mp.
17. exp HIV/
18. human immunodeficiency virus*.mp.
19. human immuno-deficiency virus*.mp.
20. acquired immunodeficiency syndrome*.mp.
21. acquired immuno-deficiency syndrome*.mp.
22. (HIV or AIDS).mp.
23. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
24. 4 and 7 and 23
British Nursing Index (ProQuest)
1. NMES
2. muscle stimulation
3. neuromuscular electrical stimulation
4. (1 or 2 or 3)
Science Citation Index Expanded (Web of Science)
1. ((muscle* or muscular or neuromuscular or neuro-muscular) and electric* and stimulat*). ti.
2. NMES. ti.
3. 1 or 2
4. (cancer* or neoplas* or malignan* or carcinoma* or tumor* or tumour* or metasta* or adenocarcinoma* or lymphoma* or leukemia*
or leukaemia*). ti.
5. ((chronic and obstruct* and (pulmonary or airway* or airflow or lung*)) or COPD). ti.
6. (((cardi* or heart) adj6 (disease* or failure)) or CHF). ti.
7. (human immunodeficiency virus* or HIV or AIDS). ti.
8. 4 or 5 or 6 or 7
9. 3 and 8
The Cochrane Library (Wiley Online Library)
1. ELECTRIC STIMULATION THERAPY single term (MeSH)
2. RESISTANCE TRAINING single term (MeSH)
3. ((muscle* or muscular or neuromuscular or neuro-muscular) and electric* and stimulat*).ti.
4. (cancer* or neoplas* or malignan* or carcinoma* or tumor* or tumour* or metasta* or adenocarcinoma* or lymphoma* or leukemia*
or leukaemia*)
5. (COPD or chronic and obstruct* and (pulmonary or airway* or airflow or lung*))
6. (((cardi* or heart) adj6 (disease* or failure)) or CHF)
7. HIV or human immunodeficiency virus*
8. 3 and (4 or 5 or 6 or 7)
key: [mp = protocol supplementary concept, rare disease supplementary concept, title, original title, abstract, name of substance word,
subject heading word, unique identifier] [ti = title].
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WH A T ’ S N E W
Last assessed as up-to-date: 6 January 2016.
Date Event Description
18 October 2016 Review declared as stable See Published notes.
H I S T O R Y
Protocol first published: Issue 11, 2011
Review first published: Issue 1, 2013
Date Event Description
14 March 2016 New citation required but conclusions have not changed This review is an update of a previously published re-
view in the Cochrane Database of Systematic Reviews
Issue 1, 2013. The search for the original review was
performed on 1 July 2012. The search period for this
update was to 6 January 2016. We identified an ad-
ditional seven studies involving 715 additional partic-
ipants (Akar 2015; Greening 2014; Maddocks 2013;
Maddocks 2016a; Sillen 2014a; Tasdemir 2015; Vieira
2014). Based on the new findings, we extended our
pooled analyses for quadriceps muscle strength (Figure
1) and exercise performance (Figure 2), and completed a
further analysis on muscle mass (Figure 3). The updated
search has not altered the overall conclusions from the
last publication of this review. However, this update in-
cludes more data, new analyses, and an assessment of the
quality of the evidence using the GRADE approach, and
we recommend previous readers of the review should
read this update.
14 March 2016 New search has been performed This review has been updated to include the results of a
new search, and ’Risk of bias’ tables and a ’Summary of
findings’ table have been added
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Figure 1. Forest plot of quadriceps muscle strength for NMES versus control.
Figure 2. Forest plot of exercise performance for NMES versus control.
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Figure 3. Forest plot of muscle mass for NMES versus control.
C O N T R I B U T I O N S O F A U T H O R S
All authors were involved in the drafting of the protocol and final review. MM and AW developed the search strategy and searched for
and obtained copies of studies for potential inclusion. SJ, WG, AW, and MM selected studies for inclusion, and all authors extracted
data from studies and assessed risk of bias. SJ, MM, andWG entered data into Review Manager 5 (RevMan 2014), carried out analyses,
and performed the GRADE assessments. All authors interpreted findings and approved the final review manuscript. MM is responsible
for conducting any future updates.
D E C L A R A T I O N S O F I N T E R E S T
SJ: none known. SJ is a physiotherapist and manages patients with respiratory conditions.
WD-CM is a consultant chest physician and manages patients with respiratory conditions. He has received reimbursement for travel
and accommodation costs from Boehringher Ingelheim arising from attendance at the European Respiratory Society Congress meeting
in 2013.
WG: none known. WG coauthored one of the studies included in this review (Maddocks 2016a). She was not involved in the data
extraction or ’Risk of bias’ assessment for this study.
IJH: none known. IJH is a consultant palliative care physician and manages patients with advanced and/or progressive conditions.
AW: none known. AW is a consultant palliative care physician and manages patients with advanced and/or progressive conditions. He
coauthored two of the studies included in this review (Maddocks 2009a; Maddocks 2013). He was not involved in the data extraction
or ’Risk of bias’ assessment for these studies.
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MM: none known. MM coauthored three of the studies included in this review (Maddocks 2009a; Maddocks 2013; Maddocks 2016a).
He was not involved in the data extraction or ’Risk of bias’ assessment for these studies.
S O U R C E S O F S U P P O R T
Internal sources
• Department of Palliative Medicine, Nottingham University Hospitals NHS Trust, UK.
AW is employed by Nottingham University Hospitals NHS Trust.
• King’s College London, Cicely Saunders Institute, Division of Palliative Care, Policy & Rehabilitation, UK.
MM, WG, and IJH are employed by King’s College London.
• Royal Brompton & Harefield NHS Foundation Trust and Imperial College, UK.
SJ and WD-CM are employed by the Royal Brompton & Harefield NHS Foundation Trust.
External sources
• National Institute of Health Research, UK.
IJH is a NIHR Senior Investigator. MM is supported by a NIHR post-doctoral fellowship and a NIHR Clinical Trials Fellowship.
MM and IJH are supported by the NIHR Collaboration for Leadership in Applied Health Research and Care (CLAHRC) for South
London. WD-CM is supported by the NIHR Collaboration for Leadership in Applied Health Research and Care (CLAHRC) for
North West London, NIHR Clinician Scientist Award, NIHR Clinical Trials Fellowship, and the NIHR Respiratory Biomedical
Research Unit, Royal Brompton & Harefield NHS Foundation Trust and Imperial College, London, UK.
• Cicely Saunders International, UK.
MM and IJH are supported by Cicely Saunders International.
• Medical Research Council, UK.
WD-CM is supported by a Medical Research Council (UK) New Investigator Research Grant.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In this 2016 updated review we considered study size as a new ’Risk of bias’ item to check for possible bias from small study size. We
also included GRADE assessments of the quality of the evidence and added a ’Summary of findings’ table. We did not include studies
examining the acute effects of NMES following a single session.
N O T E S
A new search within two years is not likely to identify any potentially relevant studies likely to change the conclusions. Therefore, this
review has now been stabilised following discussion with the authors and editors. The review will be re-assessed for updating in five
years. If appropriate, we will update the review before this date if new evidence likely to change the conclusions is published, or if
standards change substantially which necessitate major revisions.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Chronic Disease; Disease Progression; Electric Stimulation Therapy [∗methods]; Leg; Muscle Strength; Muscle Weakness [etiology;
∗therapy]; Muscle, Skeletal [anatomy & histology]; Physical Exertion [physiology]; Randomized Controlled Trials as Topic
MeSH check words
Adult; Humans
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